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Leitmotif and Quote 
 
The art of decision-making is part of a political culture.  
Changes in culture need time and involvement of all affected.  
 
“To introduce HTA in the decision-making process is like  
cultivating a garden in a snowstorm“. 
Günter Jonitz (president of Berlin´ chamber of physicians),  
Oct. 28th 2009  
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1 Introduction 
1.1 Health Technology Assessment (HTA)  
– What is it and what for to use it? 
Health Technology Assessment, abbreviated as HTA, is defined as [1] by  
EUnetHTA: 
“a multidisciplinary process that summarizes information about the medical, so-
cial, economic and ethical issues related to the use of a health technology in a sys-
tematic, transparent, unbiased, robust manner. Its aim is to inform the formula-
tion of safe, effective, health policies that are patient focused and seek to achieve 
best value. 
Despite its policy goals, HTA must always be firmly rooted in research and the 
scientific method”. 
Health Technologies are e.g. 
 Diagnostic and treatment methods such drugs, devices, surgical in-
terventions, laboratory tests or biomarker 
 Medical equipment such as catheter laboratories and  
positron-Emissions-Tomography 
 Rehabilitation and prevention methods such as occupational therapy 
psychotherapy or dietary interventions 
 Public Health programs such as screening, vaccinations, primary and 
secondary prevention programs such as interventions against alcohol 
abuse or smoking, 
 Organizational and supportive systems within which health care is pro-
vided such as checklists, IT and telemedicine or even advanced training. 
Health Technology Assessment can be applied for informing health policy on 
 investments in new equipment  
 placement and planning of big devices 
 inclusion of new interventions in benefit catalogue or 
 disinvestment of obsolete (old or ineffective) interventions 
  the available evidence for clinical guidelines for quality assurance 
 relative (cost-) effectiveness of alternative interventions 
 appropriate use of medical interventions 
 priorization in resource allocation 
and can be of use – more generally – for 
 controlled diffusion of high cost or high volume technologies  
(coverage with evidence development) 
 resource allocation based on evidence of best value 
 cost-containment in low value areas 
 increasing equitable access to effective services 
 increasing efficiency in provision of services 
 decreasing practice variations 
 improving quality 
and therefore providing input to a sustainable health care of high value  
for all citizen. 
health policy decision 
support for best value 
 
systematic  
transparent,  
unbiased 
interdisciplinary  
broad definition of 
“health technology”  
applied in many areas  
of decision making 
for a sustainable  
health care 
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It must be stressed that HTA is per defintionem a decision-support tool (only): 
HTA does NOT replace (sometimes difficult) decisions, but makes  
argumentation under pressure from interest groups a lot easier. 
HTA „opens eyes“, that (lack of or marginal) effectiveness and (a critical)  
risk-benefit ratio is in the centre of consideration and not economics. 
HTA requires a certain „civilized courage“ to question the actual innovative 
and transformative nature of new technologies and requires creativity to in-
vent new policy instruments to implement HTA. 
In contrast, decisions also always involve value-judgements such as thresh-
olds for appropriateness or medical need or for a cost-benefit ratio or clear-cut 
distinction between patient-oriented need and provider-induced demand, but 
also access and equity issues in planning etc. 
 
 
1.2 European Health Technology 
Assessment (HTA) – Why collaborating? 
In 2004, the European Commission and Council of Ministers targeted Health 
Technology Assessment (HTA) as “a political priority”, recognizing “(…) an 
urgent need for establishing a sustainable European network on HTA” [1]. 
In 2011, the “Cross-border Directive” [2] was published, writing in Art 15 
that on Cooperation on health technology assessment  
1. The Union shall support and facilitate cooperation and the exchange of 
scientific information among Member States within a voluntary network 
connecting national authorities or bodies responsible for health technolo-
gy assessment designated by the Member States. The Member States shall 
communicate their names and contact details to the Commission. The 
members of such a health technology assessment network shall partici-
pate in, and contribute to, the network’s activities in accordance with the 
legislation of the Member State where they are established. That network 
shall be based on the principle of good governance including transparen-
cy, objectivity, independence of expertise, fairness of procedure and ap-
propriate stakeholder consultations. 
2. The objectives of the health technology assessment network shall be to: 
a. support cooperation between national authorities or bodies; 
b. support Member States in the provision of objective, reliable, timely, 
transparent, comparable and transferable information on the relative 
efficacy as well as on the short- and long-term effectiveness, when ap-
plicable, of 
c. health technologies and to enable an effective exchange of this  
information between the national authorities or bodies; 
d. support the analysis of the nature and type of information 
e. that can be exchanged; 
f. avoid duplication of assessments. 
 
distinction: 
HTA vs. decision-making 
decisions:  
value-judgements  
2004 EU-Commission: 
HTA is political priority  
2011 Cross-border 
Directive:  
 
cooperation in HTA to 
avoid duplication 
 
governance: 
transparency,  
objectivity, 
independence of 
expertise,  
fairness of procedure, 
appropriate stakeholder 
consultations 
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3. In order to fulfil the objectives set out in paragraph 2, the network on 
health technology assessment may receive Union aid. Aid may be grant-
ed in order to: 
a. contribute to the financing of administrative and technical support; 
b. support collaboration between Member States in developing and shar-
ing methodologies for health technology assessment including relative 
effectiveness assessment;  
c. contribute to the financing of the provision of transferable scientific 
information for use in national reporting and case studies commis-
sioned by the network;  
d. facilitate cooperation between the network and other relevant  
institutions and bodies of the Union; 
e. facilitate the consultation of stakeholders on the work of the network. 
…….. (4. to 6. on procedures and management) 
7. Measures adopted pursuant to this Article shall not interfere with Mem-
ber States’ competences in deciding on the implementation of health tech-
nology assessment conclusions and shall not harmonise any laws or regu-
lations of the Member States and shall fully respect the responsibilities 
of the Member States for the organization and delivery of health services 
and medical care. 
A Commission call was answered in 2005 by a group of 35 organizations 
throughout Europe which led to the activities of the EUnetHTA Project [1]. 
The consequent activities of the European network for Health Technology As-
sessment EUnetHTA were organised through establishment of the EUnetHTA 
Collaboration 2009, the EUnetHTA Joint Action 2010-2012 and EUnetHTA 
Joint Action 2 2012-2015, EUnetHTA Joint Action 3 2016-2019. 
For more information on the historical and political background of a sustain-
able network for HTA in Europe, read [3-7]. 
 
 
1.3 A National HTA strategy  
The task for this paper, the development of a National HTA-strategy for Lith-
uania, is based on national needs for HTA within the national regulatory con-
text and European embedding of increased collaboration. 
A strategy is a high level plan to achieve one or more goals and is defined by 
a comprehensive way to try to pursue political ends. Strategy generally in-
volves  
 setting goals,  
 determining actions to achieve the goals, and  
 mobilising resources to execute the actions.  
A strategy describes how the ends (goals) will be achieved by the means (re-
sources). Strategy can be intended or can emerge as a pattern of activity as 
the organization adapts to its environment. It involves activities such as stra-
tegic planning and strategic thinking. Strategy is about shaping the future 
and is the attempt to get to “desirable ends with available means”. Strategic 
planning involves the formulation and implementation of the major goals and 
support by EC for 
collaboration  
collaborative HTA  
shall NOT interfere with 
MS competences in 
decision-making 
EUnetHTA:  
European network  
for HTA 
task: National  
HTA-strategy in national 
regulatory context and 
European embedding 
 
definition of strategy:  
plan to achieve one or 
more goals 
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initiatives based on consideration of resources and an assessment of the in-
ternal and external environments. Strategic planning provides overall direc-
tion and involves developing policies and plans designed to achieve these 
objectives, and then allocating resources to implement the plans. Strategic 
planning is not static in nature; the models often include a feedback loop to 
monitor execution and inform the next round of planning.  
This document, “The National HTA Strategy for Lithuania, focus medical 
devices” intends to support the 1st process, the formulation by analyzing the 
environment, making a plan for activities within the given environment, and 
developing guiding policies. Implementation refers to the action plans taken 
to achieve the goals established by the guiding policy. This 2nd step is left to 
the owners of “The National HTA Strategy for Lithuania, focus medical de-
vices”, the contractor SHAA/State Health Care Accreditation Agency. 
The “National Strategy for HTA in Lithuania, focus medical devices” pur-
sues, based on WHO’s strategy “Health for All” [8], two general aims [9]: 
 to establish a solid and comprehensive (so called “evidence-based”) 
foundation for decision making for the introduction and utilization 
of health technologies at all levels in the health care system; 
 to ensure that HTA becomes an integrated part of routine decision 
making for planning and operational policy within the health care  
system. 
The specific goals of the “National Strategy for HTA in Lithuania, focus  
medical devices” are  
1. To establish a framework to promote (enforce, facilitate) HTA uptake. 
2. To establish organizational structures for timely, efficient and  
good-quality provision of HTA-information that satisfies needs. 
3. To increase acceptance and demand for HTA-information by offering 
tailor-made services. 
4. To boost the use of HTA-information. 
 
 
National HTA Strategy 
for Lithuania, focus 
medical devices: 
 
making a plan for 
activities within the 
given environment  
general aims 
specific goals of 
National HTA Strategy 
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2 Methodology 
2.1 Analytical framework 
The Development of an HTA-strategy for Lithuania, specific focus HTA for 
Medical Devices will be based on the following analytical framework: 
1. Analysis of legal framework and regulatory context of decision-making 
 International examples of legal and regulatory linkage with policy  
environment  
 Description of Lithuanian health care and decision-making processes  
Method: Literature review for examples from countries, detailed analysis of 
Lithuanian system, interviews with Lithuanian decision-makers 
2. Analysis of utilization of HTA in health care and barriers 
 International examples for HTA utilization and applications,  
but also barriers  
 Analysis of perceived needs and bariers within the Lithuanian  
health system, and barriers  
Method: Literature review for examples, interviews with Lithuanian  
decision-makers 
3. Analysis of HTA institutionalization and financing 
 International examples for HTA embedding in institutions and  
financing of HTA  
 Analysis of existing and possible HTA embedding and financing  
in Lithuanian health system  
Method: Literature review for examples, interviews with Lithuanian  
decision-makers 
4. Analysis of human resources and capacity building 
 International examples for training in HTA and capacity building  
for “emerging” countries  
 Analysis of existing and possible training in HTA and capacity build-
ing in Lithuania  
Method: Literature review for examples, interviews with Lithuanian  
decision-makers 
5. Analysis HTA processes and products, special focus assessment  
of medical devices 
 International examples for good practice in HTA processes  
and products  
 Analysis for need of establishment of processes and products  
in Lithuania  
Method: Literature review for examples, interviews with Lithuanian  
HTA providers 
analysis of legal 
framework and 
regulatory context 
analysis of utilization 
(need and demand)  
of HTA 
analysis of HTA 
institutionalization  
and financing 
analysis of human 
resources and capacity 
building 
analysis HTA processes 
and products 
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Figure 2.1-1: Generic Analytical Framework for Development of HTA-Strategy  
for Lithuania  
 
 
2.2 Materials 
For the 5 analytical approaches the following 3 sources were used:  
 Systematic search for HTA strategy papers and extensive hand-
searches, 
 Detailed analysis of Lithuanian health care system, 
 Interviews with Lithuanian decision-makers. 
 
2.2.1 Literature Search 
The systematic literature search was conducted on 08.04.2015  
in the following Databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA)  
The search yielded 170 hits altogether. After deduplication 148 citations re-
mained for abstract screening. None of the citations reported on a “National 
HTA Strategy”, but rather broadly on on the phase of implementation and 
utilization of HTA in the different health care systems (Int J TAHC: 2000, 
Int J TAHC 2009). Two published “National HTA Strategy” papers (see Ta-
ble 2.2-1) were found by hand-searching (resp. via personal involvement in 
the Austrian HTA Strategy): 
 
3 sources 
systematic  
literature search 
 
country reports on  
HTA implementation 
hand search:  
2 national strategy 
papers 
 
from  
Austria, Denmark 
Methodology 
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Table 2.2-1: Published National HTA Strategy-papers  
Danish National Board of Health (Sundhedsstyrelsen):  
National Strategy for Health Technology  
Assessment [9, 10] – 1996 (English) 
GÖG/Gesundheit Österreich:  
Nationale HTA Strategie [11] – 2009 (German) 
 
2.2.2 System Analysis 
For a detailed analysis of the regulatory and organisational environment a 
Lithuanian expert in health care analysis (Co-Authors M. Stricka; L. Karnick-
as) was asked for collaboration. The expert was asked to give support on: 
 Description of Lithuanian legislation and regulation of health care,  
 Description of responsibilities and the decision making processes on 
public health interventions, hospital services, drugs/devices  
 The landscape of advanced training/capacity building for HTA,  
 Resource evaluation/estimation of FTE already working in HTA, 
 Role of Physicians in Guideline Development  
 
2.2.3 Interviews 
To tap into local health systems expertise surrounding HTA, 19 experts were 
interviewed in person in Vilnius and Kaunas in February, May and June of 
2015. The interviews centred around Lithuania’s key institutions relevant for 
HTA, i.e. the Ministry of Health/MoH and subordinated institutions: Nation-
al Health Insurance Fund, State Health Care Accreditation Agency, Institute 
of Hygiene, State Medicines Control Agency and the University Hospitals in 
Vilnius and Kaunas (14 experts interviewed). A second focus was put on ex-
perts from academia (research, teaching: 2 experts interviewed). Finally ex-
perts with first hand health system knowledge not institutionally affiliated 
were interviewed (3 experts interviews). The initial list of contacts was com-
piled by the State Health Care Accreditation Agency under the Ministry of 
Health. Additional contacts resulted from some of the resulting expert inter-
views. Table 2.2-2 contains the list of the experts interviewed, their institu-
tional affiliation and the date of the personal interview. 
Table 2.2-2: Lithuanian Experts interviewed 
Institution Person Date 
 Seimas of the Republic of Lithuania 
Committee on Health Affairs 
D. Mikutiene 
Chair 
Referred to 
MoH 
 Ministry of Health 
of the Republic of Lithuania 
MoH 
L. Vaideliene 
Vice-Minister 
Chair HTA Committee 
May 7th, 2015 
J. Januševičiene 
Head of Health Care Accessibility and Acceptability Unit 
Member HTA Committee 
May 7th, 2015 
June 3rd, 2015 
K. Auruškevičiene 
Head of European Union Support Division 
Member HTA Committee 
June 4th, 2015 
 
input from  
Lithuanian expert in 
health care analysis  
19 personal interviews: 
 
MoH and subsidiary 
institutions 
 
academia 
and experts with health 
system experience 
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Institution Person Date 
 Institutions under the Ministry of Health 
National Health Insurance Fund 
NHIF 
G. Kacevičius 
Acting Director 
Former member HTA Committee 
June 3rd, 2015 
N. Berntotiene 
Deputy Director for management and organization of work 
J. Sabaliene 
Head International Affairs Department 
T. Golubajeva 
Head Clinical Coding Section 
Member HTA Committee 
State Health Care Accreditation 
Agency 
SHAA 
N. Ribokiene 
Director 
in writing 
P. Morkuniene 
Chief Specialist for Accreditation 
June 5th, 
2015 
Institute of Hygiene 
Public Health Technology Center 
– Research and Technology 
Assessment UnitIoH 
R. Janoniene 
Public Health Technology Center 
Head of Research and Technology Assessment Unit  
March 17th, 
2015 
R. Valinteliene 
Head of Public Health Technology Center 
June 2nd, 
2015 
State Medicines Control Agency 
(SMCA) 
G. Barcys 
Director 
May 7th, 2015 
Vilnius University Hospital 
Santariskiu Klinikos 
D. Jankauskiene 
Advisor to Director General of Vilnius University Hospital 
Santariskiu Clinics 
May 6th, 2015 
Hospital of Lithuanian University 
of Health Sciences (LUHS) Kauno 
Klinikos 
M. Štelemekas 
Member HTA Committee 
Kaunas Clinics Hospital, Department of Innovation 
Assessment and Deployment 
Lithuanian University of Health Sciences 
Interview delegated by: 
L. Jaruševičiene 
Director for Public Health, Research and Education, 
Lithuanian University of Health Sciences 
May 5th, 2015 
 Academia: Lithuanian University 
of Health Sciences (LUHS) 
V. Grabauskas 
Chancellor of the Medical Academy 
Council Member 
Lithuanian University of Health Sciences 
May 5th, 2015 
Academia: Mykolas Romeris 
University (see also Vilnius 
University Hospital) 
D. Jankauskiene 
Professor, Institute of Political Sciences 
Faculty of Politics and Management 
Mykolas Romeris University 
May 6th, 2015 
Academia: Lithuanian University 
of Health Sciences (LUHS) 
G. Vanagas 
Professor, Department of Preventive Medicine 
Faculty of Public Health 
Lithuanian University of Health Sciences 
May 5th, 2015 
 Health system knowledge G. Černiauskas 
UAB Sveikatos ekonomikos centras (SEC) 
former Health Minister 
former Vice-Minister 
June 2nd, 2015 
Health system knowledge J. Galdikas 
former Head of SHAA 
former Health Minister 
May 6th, 2015 
Health system knowledge L. Murauskiene 
First author HiT Lithuania 
Feb. 10th, 2015 
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3 Background analyses for HTA Strategy 
3.1 Analysis of legal framework and 
regulatory context of decision-making 
3.1.1 International examples of legal and regulatory 
linkage with policy environment  
The regulatory environment for decision-making in health care is very dif-
ferent across European countries and depending on the main characteristics 
of health care organisation (Beveridge, Bismarck and mixed systems). The 
main distinction is between more centralized like in many tax-based NHS/ 
National Health Service Systems (England, Denmark) or highly decentral-
ized as in some insurance based systems (Austria, Germany). The general 
rule is that in decentralized systems new (“innovative”) interventions make 
it faster to the market (providers) than in centralized systems. 
Nevertheless the purposes of decisions are almost equal to all systems and 
the major decision-makers can therefore be analysed in a systematic manner:  
 Who (which institution) is responsible for what kind of decision? 
 Are there regulatory instruments in place to implement the decision? 
 Is the decision binding or recommendatory? 
Binding legal requirements that scientific evidence of effectiveness, safety, 
cost-effectiveness or quality assurance have to be presented before a decision 
about a public health policy (on screening programme or vaccination) and/or 
investments (in specialized medical centres or large equipment) and/or re-
imbursement (in benefit catalogues) is made are – in many countries – rare. 
Indirect references can be found, however, in some legal texts (e.g. in Aus-
tria: “the act of care must be sufficient and appropriate, but the extent of in-
evitable required not exceeding” [12]) which can be interpreted to stipulate 
such requirements:  
Most HTA-agencies in Europe are advisory bodies and have no regulatory 
function [5]. This segregation of functions is rooted in the HTA value (and 
pragmatic necessity) of independence of interest and influence from deci-
sion-makers of any kind (see detailed paragraph on independence in 3.3.1). 
Examples for the legislative foundation and the conscious segregation of 
functions are England with NICE and Germany with IQWIG.  
As written elsewhere HTA is most influential or develops the most impact if 
it is carried out for concrete decisions: 
Influential examples within Europe for  
 HTA for the In-/exclusion in the national hospital-catalogue is the 
Austrian annual programme [13, 14] 
 HTA for investments and In-/exclusion of regional and local hospital 
services are the Danish “Mini-HTA” programme [15] and the Finish 
“MUMM-Programme” [16] 
 HTA for national drug benefit assessments and according  
price-negotiations is the German AMNOG [17] 
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 HTA for regional disinvestment decisions is the Basque [18] 
 HTA for national care guidelines is the  
German AWMF S3 programme [19]. 
 Etc. 
Due to lack of direct correlations between the impact of evidence-based know-
ledge and needs-based planning few examples exist in this field of expertise, 
though highly relevant. 
 Negative example of provider-/demand-driven (not need-based) invest-
ments and worldwide are: PET-devices, Hadron-and proton centres. 
Table 3.1-1: Decision-Makers, Policy content and Regulatory Instruments (example: Austria) 
Responsible  
Institution Policy content Potential regulatory instruments Examples 
Ministry  
of 
Health 
Immunisation schedule 
Prevention programs  
Screening 
Infrastructure 
(General or age-group specific)  
In-/exclusion in public immunisation 
schedule, 
Investments in prevention programs 
Investments in early detection 
Investments in medical infrastructure 
HPV-vaccination,  
Saisonal influenza vaccination 
Mother-child care Health checks  
Mammography or Colon-Screening 
Hospitals, polyclinics,  
outpatient services 
Ministry  
of 
Health 
Hospital financing  
Hospital services 
catalogue 
Additional investments  
in equipment  
Planning of big 
equipment/ specialized 
services 
Inpatient Drugs 
DRGs or capitation 
In-/exclusion of additional services 
hospital catalogue 
Tariffs 
Conditional Coverage/Coverage with 
Evidence Development (Research) 
Infra-structural requirements for planning 
Minimal quality-volume requirements for 
specialized or frequent services 
Inpatient drug-commissions 
Re-calculation of DRGs for new 
surgical interventions or procedures 
Planning: TAVI, PET ... 
Rare interventions: Neurosurgery, 
transplantation 
Quality indicators for frequent 
interventions: Elective surgery in 
orthopaedics, birth clinics,  
positive/negative list for inpatient 
drugs (e.g. onco drugs) 
Social  
Insurance 
Institutions  
Outpatient services  
catalogue 
Outpatient-drugs 
Outpatient drug-commissions 
In-/exclusion of additional services 
Outpatient services benefit 
catalogue/basket  
In-/exclusion of new services 
Fee-for service tariffs 
Capitation 
Quality Audits/Pay-for-Performance 
Conditional Coverage/Coverage with 
Evidence Development (Research) 
Positive/negative list for inpatient 
drugs (e.g. rheuma drugs) 
Quality indicators for chronic 
conditions: asthma, diabetes,  
breast cancer 
Social  
Insurance 
Institutions  
Planning of rehabilitation 
Planning of long-term 
care facilities 
Infra-structural requirements for  
rehab services 
Access-regulation (thresholds) 
Outcome measurement 
Severity of illness indicators as 
appropriateness-criteria for  
long-term care 
Quality indicators for outcome 
assessment after cardio-rehab 
Chamber of  
Physicians 
Quality assurance  
CME/continuous 
medical training 
Clinical guidelines 
Clinical pathways 
Auditing, benchmarking 
Guidelines for chronic conditions 
Pathways for stepped care in 
diagnostics 
Regions Maintenance of hospitals 
and services 
Quality assurance + control 
Clinical risk-management 
Hygiene management 
CIRS/Critical Incident Reporting 
System-installation 
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3.1.2 Lithuanian health care system and 
decision-making processes  
3.1.2.1 Introduction to and overview of the Lithuanian 
health care system and HTA in Lithuania based on 
expert interviews 
Lithuania declared independence from the Soviet Union on March 11th, 1990 
and joined the European Union on May 1st, 2004. 
Lithuania has the second highest aged-standardized mortality from all caus-
es in the EU and the highest gender gap in life expectancy at birth. In 2010 
men were expected to live 69 years and women 70 years [20]. Lithuania has 
the lowest self-reported health status in the EU and the poorest health status 
indicators in the Baltic region [21].  
Lithuania spends 6.7% of GDP on health, of which approximately 60% come 
from statutory health insurance, 11% from tax revenues and 29% from out 
of pocket payments [22].1 More than 70% of out of pocket payments are for 
pharmaceuticals. More than half of statutory health insurance revenue comes 
from the national budget in the form of transfers for population groups in-
sured by the state (e.g. pensioners, children, individuals on parental leave) 
[20]. 
Overarching health policies are set by Parliament and government [22]. Also 
after independence Lithuania’s health care system remained centralized [21] 
and participation of stakeholders in policy-making is limited [23]. “Lack of 
transparency is very pronounced in Lithuania, decisions behind closed doors are a 
shortcoming that still exists [24].” The overall responsibility for the supervision 
of the entire health system rests with the Ministry of Health (MoH). The MoH 
is strongly involved in formulating health strategies, in drafting legal acts and 
issuing regulations for the health sector. It also runs health care facilities 
and public health institutions and has the overall responsibility for health 
system performance in the fields of individual health care, public health, 
pharmaceuticals and insurance. A large number of institutions subordinate 
to the MoH have been established in order to carry out regulatory and gov-
erning functions [25]. The most important in the HTA context are the Na-
tional Health Insurance Fund (NHIF), the State Medicines Control Agency 
(SMCA), the State Health Care Accreditation Agency (SHAA) and the Insti-
tute of Hygiene (IoH). Lithuania has two university hospitals, which play a 
strong role, one in Vilnius, one in Kaunas [21].  
The Lithuanian Health Program 2014-2025 is the main guiding health policy 
document [26]. Its central goal is to achieve an increase in average life ex-
pectancy to 77.5 years by 2025. Evaluation of the previous Lithuanian Health 
Program 1998-2010 showed an increase of average life expectancy to 73 years 
and a rapid decrease of infant mortality and of the incidence of tuberculosis.  
At the same time mortality from conditions amendable to health care in-
creased in males, as did preventable mortality (deaths that could have been 
prevented through changes in lifestyle and inter-sectoral measures impact-
ing public health) [25]. Health policy documents approved by Parliament, 
like the Lithuanian Health Program, stabilize health sector governance in 
Lithuania, even with changing ministers and governments.  
                                                             
1 Latest available figures from 2012, source WHO 2014. 
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Central and local level public healthcare institutions have constantly appeared 
among the public institutions perceived as most corrupt in Lithuania [27]. 
48% of Lithuanians report having previously paid informally/in cash for 
healthcare services. Of patients 20% report having paid for outpatient ser-
vices in the last year and 61% for inpatient (hospital) services [28]. It was 
projected that the average informal payment per physician visit is EUR 16.– 
and per hospital admission EUR 80.– in Lithuania [29]. “It depends on the 
CEO of the individual hospital if patients have to buy their own devices for surgery. 
Recently there have been 10 scandals in the media. No CEO went to jail, which 
sends a message to the community [24].” Corruption risks within the healthcare 
system also concern public procurement, given the rather weak control mech-
anisms over the procurement process [27]. “There is high corruption in public 
procurement and pharma [24].” Due to the perceived problem transparency in 
the public procurement system is constantly increasing. The most transpar-
ent are the EU financed projects. 
EU structural funds have become the main source of capital investment in the 
health system [20]. In the years 2007-2013 investment financing totaled EUR 
57 million p.a., thereof EUR 34 million p.a. from EU funds and EUR 23 mil-
lion p.a. from the state budget (EUR 6 million p.a. for the 15% co-financing 
share for EU funds and EUR 17 million p.a. for the state investment pro-
gram). Funding from the EU will be EUR 27 million p.a. in the period 2014-
2020. All healthcare investments on the national level are cleared by a com-
mittee appointed by the MoH. 
Lithuania has little experience with HTA [23]. A systematic application of 
HTA in Lithuania has been lacking. “HTA today has no influence on procure-
ment [24].” “Decisions are only rarely evidence based.” [24] Prioritization of health 
resource allocation often reflects a politically driven, rather than evidence-
based, decision-making process [20]. “There is an indecisiveness in terms of who 
is in charge of HTA in Lithuania [24].” HTA activities in Lithuania are frag-
mented. An independent HTA institution has never been established. 
For an application for NHIF reimbursement of a pharmaceutical (positive 
list) the submission of a pharmacoeconomic evaluation report to the SMCA 
has been made mandatory over a decade ago. “A large document needs to be 
provided by the applying company. There are no quality criteria for such documents 
[24].” No requirement for this report to be made by an independent institu-
tion exists [30]. “Pharmaceutical companies contract pharmacoeconomic evalu-
ations out themselves and provide the contracted experts with their own decision 
modeling [24].” The application procedure is transparent in terms of what has 
to be delivered to whom, whereas the ensuing remuneration decision itself is 
not always. “The process is well structured, if not well developed [24].” A system-
atic approach to HTA is lacking. 
To address this lack of an integrated HTA process for evidence-based deci-
sion-making, Lithuania currently sees what could historically be termed the 
third effort to establish HTA structures, after initially cooperating in 1993 
with the Swedish Council on Health Technology on training of HTA experts 
and of MoH decision makers and a second initiative in cooperation with the 
World Bank in 1999 [30]. In 2013 two organizations under the MoH (SHAA, 
for HTA on medical devices and the IoH, for HTA in public health) gained 
funding for HTA capacity building from the EU in two separate projects 
that will run until August 2015. HTA is included in a provision of the cur-
rent government’s action plan: “Introduce innovative health care technology 
assessment, deployment and application in order to improve health care ef-
ficiency and quality [31].”  
perceived corruption for 
inpatient services and in 
public procurement 
EU structural funds – 
administered by MoH – 
account for 60% of 
capital investment in 
the health system 
HTA in Lithuania: 
 
fragmented 
 
no independent  
HTA institution 
reimbursement of 
pharmaceuticals follows 
clear and transparent 
process … 
BUT company pays  
its own pharmaco-
economic dossier 
BUT no quality criteria 
already 3 initiatives to 
implement HTA: 
1993 Sweden 
1999 World Bank 
presently 2 EU capacity 
building projects  
(SHAA, IoH) 
 
HTA mentioned in 
current government’s 
action plan 
Background analyses for HTA Strategy 
LBI-HTA | 2015 21 
As a consequence the MoH established an HTA Committee in February 2014 
to coordinate HTA activities, to develop a system for the prioritization of 
health technologies to assess and to examine completed HTA reports and 
give recommendations to the minister of health based on them. The HTA 
committee is chaired by a vice-minister. Its membership is comprised of re-
presentatives from the MoH, from the NHIF, from the SMCA, from SHAA, 
from the IoH and from the two university hospitals in Vilnius and Kaunas. 
The following chapter describes regulations, actors and decision processes in 
the Lithuanian health care system in more detail. 
 
3.1.2.2 Detailed description of the Lithuanian  
health care system, decision-makers and regulations 
Market entry for healthcare services,  
medicinal products/drugs and medical devices 
Healthcare service licensing 
Healthcare is delivered by public or private healthcare institutions licensed 
for specific healthcare services. National healthcare institutions are organized 
and controlled on state and municipal levels. In general, national hospitals 
are supervised by the MoH, whereas municipalities organise local and region-
al healthcare.  
Three levels of healthcare services exist: primary, secondary and tertiary. Pri-
mary level or non-specialized level must be available to all Lithuanian resi-
dents and is orientated to the core treatments of patients. Primary level of 
personal and public healthcare services is organized by each municipality. 
Secondary and tertiary level healthcare services are in-patient and out-patient 
care and are provided by healthcare institutions organised by the municipal-
ity or the Ministry of Health. 
Lithuanian National Health System (LNHS) 
All public and those private healthcare institutions that have concluded an-
nual agreements with territorial branches of the National Health Insurance 
Fund (NHIF) for compensation of healthcare service costs are statutorily 
considered to constitute the LNHS. So far over 500 (out of the total of about 
2.000) private providers have such contracts. National regulations limit the 
capacity of institutions which do not belong to the LNHS, i.e. essentially pri-
vate healthcare institutions without the agreement with territorial branches 
of NHIF. These are not allowed to provide certain high-level healthcare ser-
vices. Also, if a non-LNHS institution sends a patient to a LNHS institution 
such a patient must pay for a visit despite the fact that the patient is insured. 
Such service costs are however compensated if LNHS institution sends the 
patient for consultation to other LNHS institution. Non-LNHS institutions 
claim that this restricts competition and therefore seeks to change the statu-
tory LNHS concept.  
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Healthcare service licensing requirement 
Healthcare service delivery is a licensed activity. License must be issued be-
fore healthcare service can be delivered. Both healthcare professionals and 
healthcare organisations must2 be licensed to deliver specific healthcare ser-
vices. MoH3 compiles a list of licensed healthcare services and determines4 
licensing requirements for professionals and institutions.  
Healthcare professionals are licensed by the SHAA following the requirements 
set in orders of the MoH. Separate orders specifying different qualification 
and experience requirements apply for every healthcare profession. General 
or specific licensing requirements (e.g. general requirements for secondary 
level adult chest surgery services5, 6) for healthcare institution to engage into 
certain healthcare service are defined by specific MoH orders. To fulfil general 
requirements healthcare institution usually must be capable to conduct spe-
cific diagnostic or laboratory tests or other specifically mentioned healthcare 
services, must have certain number of licensed healthcare professionals with 
specified number of practice years, must have certain medical equipment and/ 
or facilities at the healthcare institution applying for a specific license. 
Healthcare service licensing procedure 
Healthcare organisation licensing process is extensively regulated7 Applica-
tions with appended documents proving that premises, hygienic require-
ments, staff and their qualification, equipment and other requirements are 
met are submitted to the SHAA. SHAA adopts a decision to issue the license 
(within 30 days after the submission of a duly prepared application) or to re-
fuse it. If the application lacks required data, applicant is informed within 
20 days following the application day and may be rectified within 90 days. 
Rectification term suspends the licence issuing term. SHAA informs the ap-
plicant about the license refusal within 5 business days following the decision. 
Following the refusal the applicant may apply repeatedly without any delay. 
Issuance of a license is subject to a state fee. License is indefinite but could 
be suspended or revoked for a cause prescribed in the Rules of healthcare in-
stitution licensing8. 
Obligations of a licensed entity 
Healthcare service delivery is controlled through scheduled and non-planned 
inspections. Scheduled inspections follow the plan approved in advance by 
the SHAA, while non-planned inspection is triggered by complaint relating 
to the healthcare service quality or upon identification of license infringement 
                                                             
2 Art. 16 of the Law on Heath System 
3 14 May 2004 order No V-364 of the Ministry of Health 
4 Art. 10(6) of the Law on Healthcare Institutions 
5 Annex No 1 of the 7 November 2000 order No 603 of the Ministry of Health 
6 Item 1.1 of the 30 April 2004 No V-306 of the Ministry of Health 
7 The order is prescribed by the Law on healthcare institutions, the Rules of health-
care institution licensing approved by 2 March 2007 order No V-156 of the Ministry 
of Health, the List of licensed healthcare services approved by 14 May 2004 order 
No V-364 of the Ministry of Health and specific Ministry of Health orders laying 
down licensing requirements for each specific healthcare service 
8 The Rules of healthcare institution licensing approved by 2 March 2007 order No 
V-156 of the Ministry of Health 
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by controlling authorities. Supervision of licensed activity takes either of two 
forms: the request to provide relevant documentation or an on-site inspec-
tion. SHAA informs the healthcare institution and the territorial NHIF (if 
the healthcare institution has concluded a contract with it) about the identi-
fied infringement (see also section on Quality Assurance for more details). 
Accreditation and certification are both available in Lithuania; however, both 
are voluntary forms of healthcare quality control and service level develop-
ment. None of them is required to start or to maintain healthcare service de-
livery (see also section on Quality Assurance for more details). 
 
Medicinal products/drugs 
Medicinal products can be marketed in Lithuania only if registered on na-
tional or the EU level or if enrolled into the list of medicine of parallel im-
ported products. The SMCA adopts orders to grant, renew, amend, suspend 
or withdraw medicinal product marketing authorisation9 Orders are published 
on the SMCA website within 3 working days after their adoption.  
Medicinal product marketing authorization requirement 
Product registration follows the Directive 2001/83/EC and other EU stand-
ards. Similarly to other EU countries, products need to receive SMCA mar-
keting authorisation (MA) under national, mutual recognition procedure (MRP) 
or decentralised procedure (DCP) or to possess a centralised European med-
icines agency (EMA) approval. Parallel importation of both nationally or cen-
trally registered products is also allowed. 
Registration procedure is chosen according to the type and territorial scope 
of MA sought: 
1. The manufacturer who wishes to obtain marketing authorisation sim-
ultaneously in several EEA (European Economic Area) states, includ-
ing Lithuania, for a medicinal product that has not yet been granted 
marketing authorisation in any of the EEA states may choose to apply 
under a decentralised procedure. He must supply a dossier identical to 
that which is submitted to the competent authority/authorities of an-
other state/other states together with the application. 
2. The manufacturer who wishes to obtain marketing authorisation of a 
medicinal product in any EEA state, including Lithuania, other than 
the state of an existing registration, may choose to apply under a mutu-
al recognition procedure. He must supply a dossier identical to that based 
whereon the medicinal product was granted marketing authorisation 
by the first state with all the subsequent supplements. 
3. The manufacturer who wishes to obtain marketing authorisation of a 
medicinal product only for Lithuania, and no marketing authorisation 
has been granted for this product in any other EEA may choose to 
apply under a national procedure. 
 
                                                             
9 Medicinal product national registration is primarily governed by the Law on Phar-
macy and the Rules on issuing medicinal product marketing authorisation approved 
by 10 July 2007 order No V-596 of the Ministry of Health 
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Along with the application, results of pharmaceutical (physical-chemical, 
biological or microbiological) pre-clinical (toxicological and pharmaceutical) 
tests and clinical trials must be submitted. Without prejudice to the protec-
tion of industrial property and commercial secrecy, they may be dispensed 
with if the applicant can demonstrate that the medicinal product is a generic 
medicinal product of a reference medicinal product which has been author-
ised for at least 8 years in a EEA state or in the Community (so-called data 
exclusivity period of the reference medicinal product). Such generic medicinal 
product may only be supplied to the market after the lapse of not less than 
10 years from the day of granting the reference medicinal product initial mar-
keting authorisation (the so-called 2-year market exclusivity period of a refer-
ence product). This 10-year exclusivity period may be extended for a maxi-
mum of one more year if during the initial 8 years of the said 10 years the 
marketing authorisation holder registers one or several new therapeutic in-
dications, which according to scientific evaluation performed prior to the clin-
ical benefit compared with the present treatment. 
Medicinal product marketing authorisation may be granted to a legal person 
established in any EEA state who is a producer of the medicinal product or 
who has entered into a contract with the producer setting forth mutual rights 
and obligations.  
Medicinal product marketing authorization procedure 
National MA grant procedure: The standard form10 medicinal product mar-
keting authorisation application is submitted to the SMCA. Extensive data 
and documentation including description of GMP compliant manufacturing 
methods, preclinical and clinical trials, summary of product characteristics, 
patient information leaflet is appended to the application. SMCA Medicinal 
product registration division finishes application formalities examination 
within 20 working days following the submission. Applicant is informed about 
the application deficiency via email and has to rectify deficiencies within 20 
working days following the SMCA request. Failure to do so in time results in 
application rejection. Application is rejected if requested data is not clarified 
within 90 days following the SMCA request and product samples should be 
presented within 20 working days following the SMCA request. Failure to ful-
fil SMCA request in time results in rejection of the application.  
To renew medicinal product marketing authorization marketing authorization 
holder must submit an application11 to the SMCA. Decision on renewal of 
documents is adopted within 90 days after submission of application. Appli-
cation deficiencies are governed in the same order as prescribed for MA ap-
plications. Based on pharmacovigilance data sufficiency SMCA decides wheth-
er to renew the authorisation and if so whether the MA is indefinite or needs 
further renewal after 5 years. 
 
                                                             
10 As approved by the State Medicines Control Agency under the Ministry of Health 
according to the template provided by the European Commission in Volume 2B of 
the publication “The rules governing medicinal products in the European Union” 
11 Application form approved by the SMCA according to the template provided by 
the European Commission in Volume 2C of the publication “The rules governing 
medicinal products in the European Union” must be supplemented with additional 
data” 
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MA variation procedures are conducted under the order prescribed by the 
Regulation No 1234/2008. Variation is a change to a MA after its grant. A 
number of variations (ranging from correction of a typo in the patient in-
formation leaflet to an addition of a new substance to the product formula) 
exist. Regulation No 1234/2008 and European Commission guidelines12 fa-
cilitate the classification of variations and prescribe the order to implement 
the variation. 
The MA of a medicinal product shall be granted or a justified refusal to 
grant the marketing authorisation shall be given not later than within 210 
days from the day of receipt of the properly submitted application. The time 
of the applicant providing additional documents, information and, as neces-
sary, verbal and/or written explanations required by the SMCA is included 
in the time of examination of the application. 
 
Medical devices 
Medical devices can be marketed in Lithuania only if notified to the SHAA 
and properly labelled. No registration requirement exists for medical devic-
es. Separate legal acts set regulatory requirements for medical devices13, in-
vitro medical devices and active implantable medical devices. 
Medical device notification requirement 
Before a medical device is put on the market a representative sample must 
undergo the EC type examination and receive EC type certification from the 
Notified Body (NB) (private entity approved for certification of medical de-
vice sample by the designating authority (SHAA in Lithuania)14 under the 
procedure prescribed by the EU15 and local laws16). European Commission 
administers a list of NB for active implantable medical devices17, medical 
devices18 and in vitro medical devices19. Certification proves that the device 
sample complies with applicable medical device regulations. Technical com- 
                                                             
12 http://ec.europa.eu/health/files/betterreg/pharmacos/ 
classification_guideline_adopted.pdf  
13 Medical norm MN 4:2009 „Technical Regulations on the Safety of Medical Devices“ 
approved by the Order No V-18 of 19 January 2009 of the Health Minister of the 
Republic of Lithuania is the main piece of legislation governing the market entry 
requirements for medical devices. 
14 Item 2.1 of 30 July order No V-732 of the Ministry of Health  
15 Commission implementing regulation (EU) No 920/2013 of 24 September 2013 on 
the designation and the supervision of notified bodies under Council Directive 
90/385/EEC on active implantable medical devices and Council Directive 93/42/ 
EEC on medical devices 
16 Government 4 July 2006 resolution No 674; 30 July order No V-732 of the Ministry 
of Health 
17 See http://ec.europa.eu/enterprise/newapproach/nando/ 
index.cfm?fuseaction=directive.notifiedbody&dir_id=8&type_dir=NO%20CP
D&pro_id=99999&prc_id=99999&ann_id=99999&prc_anx=99999 
18 See http://ec.europa.eu/enterprise/newapproach/nando/ 
index.cfm?fuseaction=directive.notifiedbody&dir_id=13&type_dir=NO%20CP
D&pro_id=99999&prc_id=99999&ann_id=99999&prc_anx=99999 
19 See http://ec.europa.eu/enterprise/newapproach/nando/ 
index.cfm?fuseaction=directive.notifiedbody&dir_id=8&type_dir=NO%20CP
D&pro_id=99999&prc_id=99999&ann_id=99999&prc_anx=99999 
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pliance of each manufactured medical device with the representative sample 
is approved by the manufacturer following the EC verification procedure and 
by affixing a CE marking to the product. Once medical device is manufac-
tured, notification requirement and appropriate labelling and usage instructions 
must be in place to put medical device on the market.  
No Lithuanian entities are designated to perform NB functions at the moment. 
Notification procedure 
SHAA must be notified20 when class IIA, IIB and III and custom made active 
implantable medical devices are placed on the market. Class I medical devices 
need no notification. The manufacturer putting the medical device on the 
market has to notify SHAA within 14 business days following the delivery of 
the device to the market. Notification is performed in a standard form notice. 
SHAA registers the device and informs the notifying person within 5 business 
days from the submission. Labels and usage instructions must be presented 
along with the notification of class IIa, IIb and III and custom made active 
implantable medical devices.  
If the medical device is a piece of electric or electronic equipment, in ad-
dition to the notification procedure the supplier (either manufacturer or dis-
tributor representing it) must register with the Registry of Manufacturers 
and Importers. This registration must be done before the device is put on the 
market. This registration incurs certain waste management obligations21. 
SHAA must also be informed about any change in notified data. Such noti-
fication must be submitted within 14 business days following the change of 
data by the person who made initial notification. 
Labelling and usage instructions 
Each medical device must have information to ensure its safe use. Such in-
formation is provided on the label and instructions for use. All medical de-
vices, other than devices which are custom-made or intended for clinical in-
vestigations, must bear a CE mark accompanied by the identification num-
ber of the NB responsible. Instructions for use must be included in the pack-
aging for every medical device, except devices of class I or II a, if they can be 
used safely without any such instructions. Detailed requirements for the us-
age instructions and labels correspond to those specified in the Annex 1 of 
Directive 93/42/EEC concerning General Medical Devices. All medical de-
vices falling in to the category of electric or electronic equipment must also 
be labelled accordingly. 
 
                                                             
20 Notification procedure is governed by the are established by the Rules on Submis-
sion of Information about IIA, IIB, III Class and Custom Made Active Implanta-
ble Medical Devices approved by the Order No V-938 of 16 November 2009 of the 
Ministry of Health 
21 Obligations are governed by Art. 341 of the Law on Waste Management and the 
Rules on Registration of Manufacturers and Importers approved by the Order 
No D1-291 of 27 May 2009 of the Ministry of Environment Protection 
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Investment in healthcare 
Public healthcare service providers have very limited funds to invest. Sav-
ings from the services provided are usually used for routine maintenance, 
whereas state and municipal budgets and the EU structural assistance (in-
cluding assistance from Switzerland and EEA Grants) are the main sources 
for capital investment to healthcare in Lithuania. 
 
State Investment Programme 
On the national level State Investment Programme (the Programme) plays a 
major role as capital investment for public healthcare institutions (both owned 
by the state and by municipalities). The Programme is approved by the Gov-
ernment for at least 3 years period22. Each governmental authority or institu-
tion is setting programme priorities for their governance domain23. Invest-
ments in health care are governed by the MoH. New priorities for investments 
in health care were established in 201324: 
1. Mother and child health improvement; 
2. Disease prevention and control assurance; 
3. Decreasing morbidity and mortality from non-communicable diseases; 
4. Renovation of institutions infrastructure. 
Closely following these priorities healthcare institutions develop investment 
projects. Application to include the investment project in the State Investment 
Programme should be submitted to the MoH. The investment projects selec-
tion committee, appointed by the MoH, selects projects for funding. Project 
planning, financing, implementation and control procedures are described in 
the MoH order No V-108125. 
Projects are selected according to selection criteria, healthcare institution per-
formance indicators and policy principles. For the 2013/15 investment period 
the following policy principles were approved26: 
1. to focus on funding low number but high impact investment projects, 
in order to complete at least several projects and to allocate more funds 
to ongoing projects which have already achieved at least half of the 
required funding and to fast-track them; 
2. to intensify funding for projects executed by healthcare institutions 
which are prospective in terms of economic and medical indicators 
and which are expected to aggregate regional patient flows; 
3. to account the proportion of total funds allocated for a specific project 
to date; 
4. to finance projects challenging problems of particular relevance: updat-
ing sterilization units, replacing obsolete lifts, eradicating emergency 
condition and so forth.  
5. since 2013 to fund projects of particular importance only, ones strength-
ening healthcare institution and increasing its regional importance. 
                                                             
22 Art. 14 of the Law on Investments  
23 The rules for governance of the capital investments from the state budget approved 
by the April 2001 resolution No 478 of the Government. 
24 Approved by the April 2013 order No V-346 of the Ministry of Health. 
25 Approved by the December 2010 order No V-1081 of the Ministry of Health.  
26 Approved by the January 2013 order No V-20 of the Ministry of Health.  
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Selection criteria for investment projects are annually revised and approved 
by the MoH. Currently the following criteria27 are in force: 
1. ongoing investment project which requires up to EUR 300,000 for 
completion; 
2. the investment project is intended to solve urgent problematic cases, 
when supporting documents are presented; 
3. investment project is co-financed with the assistance of EU structural 
or other international funds; 
4. investment project co-financed from municipal budget and/or  
institution funds;  
5. continuing investment project; 
6. investment project, when institution has implemented quality  
management system(s); 
7. Investment projects on specialized out-patient, emergency care,  
day-care, day-surgery and observation services development, intended 
to minimize in-patient services. 
8. municipality contributes own funds for preventive activities 
9. new investment project, which starts and ends during the current 
budget year and cost up to EUR 100,000. 
 
Investments from EU funding and co-financing 
Total allocation of EU structural assistance for Lithuania in all policy sectors 
for the period 2007-2013 (from the European Social Fund, European Regional 
Development Fund and Cohesion fund) amounts to more than EUR 6.775 bil-
lion (EUR 7.423 billion – including national co-financing). This almost equals 
an additional annual Lithuanian state budget. EU structural assistance allo-
cated to operational programs administered by the MoH amounts to almost 
EUR 300 million (including national co-financing) for that period. 
EU structural assistance for Lithuania for the period 2007-2013 will be allo-
cated in accordance with the national general strategy: the Lithuanian Strat-
egy for the use of European Union Structural Assistance for 2007-2013 (ap-
proved the European Commission on the 26th of April, 2007) and with 4 op-
erational programs for implementation of this strategy28: 
1. Operational Programme for the Development of Human Resources 
for 2007–2013; 
2. Operational programme for the Economic Growth for 2007–2013; 
3. Operational Programme for Promotion of Cohesion for 2007–2013; 
4. Technical assistance Operational Programme for 2007–2013. 
                                                             
27 Approved by the April 2013 order No V-346 of the Ministry of Health.  
28 Approved by the April 2007 in the European Commission 
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In accordance with the operational policy area, the MoH is responsible for 
the implementation of the first objective “To provide high quality and afford-
able health care services” of the second priority “Quality and accessibility of 
public services: infrastructure of health care, social care and education” of the 
Operational Programme for Promotion of Cohesion for 2007-2013. Twelve 
measures were defined by the Government to achieve this objective (see Ta-
ble 3.1-2)29. 
Table 3.1-2: Funds allocated and contracted for Operational Programmes under  
MoH administration for the year 2007 to 2013 (including EU Funds and national co-financing funds) 
No Measure 
Number 
of 
projects 
Funds  
allocated  
EUR million 
Contracts  
signed  
EUR million 
1 Decreasing morbidity and mortality from 
cardiovascular diseases (National) 
1 45.318 45.318 
2 Updating infrastructure of health care institutions 
providing emergency services in case of injuries and 
other external causes (National) 
16 50.155 50.882 
3 Updating infrastructure of ambulances and urgent 
consultation providers (National) 
1 7.233 7.899 
4 Early diagnostics of oncological diseases and  
full-fledged treatment (National) 
10 49.184 49.145 
5 Establishment of differentiated complex psychiatric 
centres for child and family (National) 
5 3.038 3.199 
6 Modernization of Psychiatric in-patient care (National) 8 4.024 4.181 
7 Modernization of infrastructure for mental health 
service surveillance (National) 
1 0.189 0.189 
8 Establishment of psychiatric day hospitals (centres) 
(Regional) 
27 9.820 10.055 
9 Establishment of crisis intervention centres (Regional) 5 2.436 2.437 
10 Development of outpatient, palliative and nursing 
services and optimization of inpatient services 
(National) 
109 99.990 101.038 
11 Development of Public health care infrastructure in 
municipalities (Regional) 
27 4.011 4.063 
12 Infrastructural investments for provision of public 
outpatient and inpatient services delivered by private 
health care institutions (Open call) 
37 5.011 5.008 
 Total 247 280.409 283.414 
Source:  EU structural assistance information management and supervision system30. 
 
All projects financed from the EU Structural Funds for the period 2007-2013 
must be completed by the end of September 2015. By the May 2015, 91 % 
(EUR 255.308 million) of contracted EU funding has been absorbed.  
                                                             
29 Approved by the July 2008 resolution No 787 of the Government. 
30 Ministry of Finance. Information updated on the 30 of January 2012 according to 
the data from EU structural assistance information management and supervision 
system Retrieved on the 15 of May, 2015. 
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EU funded projects administration process for the period 2007-2013 
EU funded projects are administered and financed in accordance to the rules 
established by the Government31. There are three different types of EU fund-
ed projects: national, regional and open tenders. National and regional pro-
jects are planned by compiling and approving national and regional projects’ 
lists. National level projects are planned by ministries and (or) other state 
institutions, whereas 10 Regional Development Councils are responsible for 
planning of the regional projects. The MoH as an interim authority adminis-
ters 8 measures covered by the national selection. National projects are planned 
in accordance with National projects’ planning procedure of the MoH32. 
 
Figure 3.1-1: Administration of EU Funds (2007-2013) 
Key national strategic documents for the implementation of the EU Cohe-
sion policy are the Partnership Agreement and the Operational Programme 
for EU Structural Funds Investments for 2014-2020 approved by the Europe-
an Commission in 2014. The Lithuanian multi-fund Operational Programme 
brings together 5 EU investment funds with total allocated budget of EUR 
8,386 billion. 
                                                             
31 The rules for administration and finance of EU projects approved by the December 
2007 resolution No 1443 of the Government. 
32 Approved by the April 2008 order No V-299 of the Ministry of Health (updates: 
September 2011, No V-834; June 2012, No V-648). 
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The Operational Programme is based on National Progress Programme for 
2014–202033 which aims to implement provisions of the EU strategy “Eu-
rope 2020” and Lithuania’s progress strategy “Lithuania 2030”. Ministry of 
Finance is the managing authority of the EU funding for 2014-2020 and the 
MoH is assigned to administer two objectives of the priority No 8 “Social in-
clusion and poverty reduction”:  
 to improve quality and access to health care for the target populations 
and to reduce health inequalities (European Regional Development 
Fund (ERDF)); 
 to decrease health inequalities by improving quality and accessibility 
of health care for the target populations and by promoting healthy ag-
ing (European Social Fund (ESF)). 
The MoH has allocated EU structural investment funds to implement aims, 
objectives and measures in individual health development priority areas (see 
Table 3.1-3)34.  
Table 3.1-3: Planned Budgets from EU Structural Funds for  
Operational Programmes under MoH administration for the year 2014 to 2020 
0 Priority area 
Planned budget from  
EU structural funds for 2014-2020 
Total 
EUR 
mio 
Incl.  
ERDF funds 
EUR mio 
Incl.  
ESF funds 
EUR mio 
1. Reducing health inequalities 
1.1. Increasing effectiveness of tuberculosis prophylaxis, diagnosis and 
treatment  
17.4 11.3 6.1 
1.2. Improving access to prevention, treatment and social reintegration 
services for people addicted to alcohol and other psychoactive substances  
7.0 5.1 1.8 
1.3. Improving access to effective health care for persons with disabilities  11.0 9.6 1.4 
1.4. Decreasing morbidity and premature mortality from diseases of 
circulatory system  
20.9 16.2 4.6 
1.5. Decreasing morbidity and premature mortality from cerebrovascular 
diseases  
42.0 36.2 5.8 
1.6. Preventing injury and decreasing disability and mortality from external 
causes 
14.5 8.1 6.4 
1.7. Assuring of oncological diseases prevention and effective treatment  22.3 17.4 4.9 
1.8. Assuring health promotion, disease prevention and effective treatment 
for children  
46.3 36.8 9.6 
Total  181.3 140.7 40.6 
2. Healthy aging 
2.1. Developing of health promotion and other preventive health services  16,0 11,6 4,4 
2.2. Falls prevention 1.4 – 1.4 
2.3. Improving mental health 3.5 – 3.5 
2.4. Establishing health promoting conditions at work 3.5 2.3 1.2 
2.5. Organizing network for combined nursing and geriatric care provision  12.2 11.0 1.2 
2.6. Preventing inflammatory and degenerative rheumatic diseases and 
diseases caused disability  
2.9 2.3 0.6 
Total  39.4 27.2 12.2 
                                                             
33 Approved by the November 2012 resolution No 1482 of the Government. 
34 Approved by the July 2014 order No V-795 of the Ministry of Health. 
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Although rules for the administration and financing of EU structural invest-
ment projects for 2014-2020 have not been approved yet, it is likely to be 
similar to ones of the 2007-2013 funding period. 
 
Investments on Large Scale Medical Devices 
All public healthcare institutions are required to obtain the approval from the 
MoH when purchasing large scale medical devices (from the list approved)35, 
or when estimated acquisition price (value added tax included) of the device 
including accessories is greater than EUR 145,000. 
The SHAA collects data on large scale medical devices, costing over EUR 
29,000, or those bringing an annual revenue from the NHIF to providers of 
more than EUR 290,000. The information collected includes financial and 
usage intensity indicators for public providers; private providers not contract-
ed by the NHIF only report starting and final dates of the usage of the equip-
ment36, 37 In the table below, SHAA information on the use of large scale med-
ical devices is presented. 
Table 3.1-4: Large scale medical devices operated in 2013 and  
newly acquired in 2014 by the public and private health care institutions in Lithuania 
Device 
In use  
in 2013 
Newly acquired 
in 2014* Total 
Computed tomography (computed tomography X-ray equipment) 68 1 69 
Magnetic resonance tomography (magnetic resonance imaging equipment) 33 0 33 
Mammograph (mammographic X-ray equipment) 37 0 37 
Ultrasound device 684 36 720 
Angiography (a specialized X-ray angiography equipment) 26 0 26 
Gamma camera (gamma ray camera) 9 0 9 
Linear (electron/photon) accelerator 11 0 11 
Diagnostic X-ray equipment 396 7 403 
Positron emission tomography (PET) 1 1 2 
* data presented from public health care institutions only 
Source: SHAA 
 
In 2010/12 EUR 51.8 million from the State Investment Programme (includ-
ing EUR 47.5 million EU and co-financing funding and EUR 4.3 million State 
budget funding) were spent on the acquisition of large scale medical devices, 
which accounts for 25 per cent of the total health care investment programme38. 
The applications are considered in the Coordination committee for large med-
ical devices39. The members of the committee are personally appointed by the 
MoH. The committee decisions are based on formal criteria40: 
                                                             
35 Approved by the October 2012 order No V-947 of the Ministry of Health. 
36 Approved by the May 2010 order No V-383 of the Ministry of Health. 
37 Approved by the March 2011 order No T1-224 of the head of SHAA. 
38 According to the Operational Audit Report: How diagnostic procedures with Large 
Scale Medical Equipment are organized?/Approved by November 2013 of the Na-
tional Audit Office of Lithuania.   
Internet https://www.vkontrole.lt/failas.aspx?id=3086 [retrieved on 19/05/2013]. 
39 Approved by the June 2013 order No V-585 of the Ministry of Health. 
40 Approved by the May 2013 order No V-457 of the Ministry of Health. 
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 Demand meets the provision of strategy papers; 
 Number of particular devices in Lithuania is not higher than  
EU average; 
 Current/planned workload of particular device is not lower than  
the national average; 
 Planned services meets evidence based needs; 
 A qualified health care personnel is provided; 
 Particular devices are geographically equally distributed; 
 Operational life of the concurrent medical device exceeds  
recommendations. 
 
Funding and reimbursement of healthcare services,  
medicinal products/drugs and medical devices  
Healthcare funding 
Most of health services are publicly funded (national or municipal budgets 
based on compulsory health insurance funds (CHIF)), but for certain services 
also privately funded (direct patient payments, private health insurance) health 
care provision exists. Despite being advocated by the private sector, the pri-
vate health insurance is still at the early stage and with the coverage of about 
1% of population is of limited significance to the system at large. 
CHIF is the main source for funding public healthcare and is comprised of 
public health insurance instalments paid by all economically active residents 
(around 40% of total CHIF income) as well as of state insurance contribu-
tions (about 60% of total CHIF income) on behalf of the rest of the popula-
tion, mainly socially vulnerable groups.  
Different funding schemes exist. Primary care is based on capitation payment. 
Additional payments for certain services (e.g. home visits to newborns, cer-
vical cancer screening, etc.) and for exceptional services are available. Second-
ary and tertiary services rely both in inpatient and outpatient care basically 
on per case payments from CHIF. About 70% of CHIF is used for these pur-
poses. The rest is divided among reimbursement of medicines (around 17%), 
medical rehabilitation, centrally purchased medicines and preventive health 
programmes.  
 
Healthcare cost compensation practice 
Healthcare activities for the LNHS are compensated via a complex system of 
allocating “points” (each point has a base price, but not always a fixed value) 
to services. Compensation is calculated by multiplying the numbers of ser-
vices delivered with the acquired “points”. The sum is transferred through 
the territorial branches of NHIF. A contract sum is negotiated with the health-
care institutions prospectively in the beginning of the year and is generally 
based on the historical service demand (figures from previous years). The 
amount that is actually transferred to the institution is determined by mul-
tiplying the actual base price with the total number of healthcare service 
points. But the contracted sum cannot in any way be exceeded. 
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Healthcare institutions are free to individually determine the amount of ser-
vices that they will deliver over the year. Outperforming, i.e. delivering more 
services then the amount set in the contract reduces the value of the base 
price. Healthcare institutions are however precluded from deciding to lower 
the amount of service delivery because the maximum value of base price is 
capped at a standard rate. This complicated compensation mechanism allows 
to manage public healthcare spending when the actual service demand cannot 
be controlled. As a result of this compensation system, the increase in patient 
flows does not increase the total healthcare costs of the institution (neither it 
increases the revenue). 
In principle, base price calculations are a financial solution for balancing the 
rising demand for healthcare services and the limited income of CHIF re-
sources.  
 
Procurement models in the public sector 
Public sector institutions (hospitals) use the following main models  
to procure pharmaceuticals: 
 Certain drugs are procured through the Central Procurement Organ-
isation (CPO). This allows public institutions to avoid complicated 
public procurement procedures. Instead, they only publish relevant in-
formation about certain drug on the CPO public catalogue. CPO or-
ganises the competition among all potential suppliers on the lowest 
price basis. Public institution then must enter into procurement con-
tract with the winner; 
 Other drugs are procured through hospital tenders; 
 Expensive patented medicines (e.g. antiretroviral drugs, some cancer 
therapies) are procured by CHIF through centralised tenders. As of 
2013 CHIF has changed the way patented medicines with a single pro-
vider are procured. Patented medicines amount to 80-95% of total ex-
penditure on centralized tenders and because of the single provider 
cost-containment is hard to achieve.  
The remaining problem with CPO and public procurements is that in some 
instances the price for the same product differs up to several times for dif-
ferent hospitals.  
 
Pricing of drugs 
In 2010 statutory pricing was introduced to all non-reimbursable pharma-
ceuticals and decreased the price level by about 10%. As a result of certain 
price containment measures, in 2010 CHIF expenditure on reimbursement 
pharmaceuticals fell for the first time since 2002. Pricing schemes for reim-
bursable and non-reimbursable pharmaceuticals vary, however maximum 
mark-ups apply for both. This preserves the competition among the respec-
tive distribution chain players. 
Marketing Authorization Holders (MAH) must declare prices for each of the 
non-reimbursable prescription and OTC products to the MoH. With minor 
exceptions, failure to do so prohibits the sale of such product to the general 
public. Prices are regulated by setting maximum wholesale and retail mark-
ups for such products. Distributors and pharmacies take the declared price 
for granted and freely apply mark-up within the set limits which range up to 
18% and up to 30% (depending on the declared price) for wholesalers and 
retailers respectively. 
intention:  
 
neither to intervene in 
determination of 
number of services  
nor to let the costs 
explode by maximizing 
number of services 
balancing between 
demand and CHIF 
income 
Central Procurement 
Organisation for some 
drugs 
 
or 
 
hospital tenders 
 
or 
 
centralized CHIF tenders 
suboptimal:  
different prices for 
different institutions 
2010: 
statutory pricing for 
drugs led to decrease  
of prices 
also non-reimbursable 
and OTC products are 
price-regulated:  
 
reimbursable and  
non-reimbursable 
pharmaceuticals:  
Background analyses for HTA Strategy 
LBI-HTA | 2015 35 
Pricing of reimbursable products within the distribution chain is similar to 
that of non-reimbursable products. Manufacturer’s price should not exceed 
the declared price while the wholesale and retail prices for retailers and the 
patient respectively are calculated by adding statutorily set maximum whole-
sale and retail mark-ups of up to 14% and up to 22% respectively (depending 
on the purchase price).  
 
Main measuresfor cost-containment for drugs 
The following main measures for optimisation of CHIF spending apply for 
reimbursable pharma products: 
 Grouping products with different active substance but interchangeable 
therapeutic action for the basic price  
 “Price tunnel” for generics; 
 “Price tunnel” for products entering the group with products of the 
same active substance from more than 3 manufacturers; 
 “Price tunnel” for new products entering the group that had first  
generic entry in 2004-2009; 
 Requirement for new packaging entering the group with products of 
the single manufacturer to be cheaper; 
 Reimbursing composite products according to the component with 
lowest price; 
 Price negotiations are started with the supplier when the declared price 
exceeds 95% of reference country average. Portfolio and other trade-
offs are acceptable but very rare; 
 Cost-volume agreements may be voluntary or mandatory. The latter 
are concluded with the manufacturer in specific saturations (e.g. when 
all the products within the therapeutic group belong to the single man-
ufacturer; when the product required more than 1% of CHIF or EUR 
290,000 for reimbursement last year). These agreements oblige the 
supplier to return the amounts exceeding certain agreed cap.  
 
Reimbursement procedures for drugs 
Only prescription drugs are reimbursed. New applications for reimbursement 
are only successful for products with high pharma-economic and therapeutic 
value calculated in comparison with the closest alternatives. The Pharmaceu-
tical Reimbursement Commission performs this assessment and delivers its 
non-binding decision to the Compulsory Health Insurance Council for fur-
ther scrutiny. Compulsory Health Insurance Council and the NHIF both de-
liver separate reimbursement recommendations and the MoH adopts the fi-
nal decision. Applications are submitted to and scrutinized by the Pharmacy 
department of the MoH which also calculates the base price and highest re-
tail prices for products. Products are enrolled into the reimbursable pricelists 
with the MoH order. 
Every medicinal product reimbursement application must include a pharma-
co-economic analysis prepared according to the Recommendations adopted 
by the MoH.41 The Recommendation is based on a classic cost-benefit assess-
ment of product efficacy and safety data and treatment costs, compared and 
contracted against the closest therapeutic alternative. The main methodology 
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principles suggested for the assessment include: the analysis should be coun-
try-specific; analysis must focus on healthcare and economic comparison; as-
sessment should be performed for approved dosages and indications; specific 
pharmaco-economic methods must be used; reliability of results must be criti-
cally evaluated; cost comparison for the achievement of treatment result must 
be performed; selected assessment methods must be reasoned.  
The reimbursable product pricelist is issued once a year with pricelist sup-
plements appearing irregularly several times a year. Periodicity for issuing 
pricelist supplements is not statutorily set and varies depending on a number 
of successful reimbursement applications. Due to the rules encouraging price 
competition among reimbursable products with the issuance of each pricelist 
supplement the base price for particular product group may change or cer-
tain product may even drop off the list. Irregular issuance of pricelist sup-
plements reduces revenue predictability for reimbursable product providers. 
The impact on the budget is also considered when adopting positive reim-
bursement decision. If when compared with the closest alternatives the prod-
uct (already with sufficient pharma-economic and therapeutic value) requires 
additional budgetary funds it falls within the reserve list. The list includes 
products that could be reimbursed when required funding becomes availa-
ble. Currently, the regulations are vague on what particular conditions these 
reserve products could be moved from the reserve list into reimbursable prod-
uct list and introduce some uncertainty for reserve list product providers. 
Along with the decision to reimburse the MoH approves the base price and 
the highest retail price. Base price is calculated according to specific formula 
which includes the average of reference country price (international refer-
ence pricing). 
Reimbursement of generics follows the so-called “price tunnel” model. To be 
reimbursed the first generic must offer a price which is no less than 50% lower 
than the innovative alternative to be included into the reimbursable list. The 
second and the third generic to enter the list must further lower the price so 
that it does not exceed 85% of the cheapest product in the group and should 
not exceed 95% of the reference price average. Each further generic entrant de-
creases the price even more. “Price tunnel” for biosimilars is even more rigid.  
Currently, 100%, 90%, 80%, 50% (of a base price) reimbursement rates ap-
ply, thus leaving the rest of the sum for the patient co-payment. All reimburs-
able products except insulin have patient co-payment. The industry often 
draws attention that the consumption of products with 50% reimbursement 
rate is relatively low allegedly due to the high co-payment. Manufacturer 
aiming for higher sales can offer discounts for patient co-payment under a 
strictly regulated procedure. Discount cannot be offered in any other way. 
 
Reimbursement and pricing of medical devices 
Reimbursement of medical devices (medical aid devices) is organized under 
same system as medicinal products. The MoH has approved a list of condi-
tions for which medical treatment would be compensated from the national 
budget. Base and the highest retail prices of reimbursable medical devices are 
approved only for those medical devices that have been listed in the List of 
Diseases and Reimbursable Medical Devices for their Treatment (so called 
C-List) approved by the MoH, and in respect whereof an application has 
been received for including them in the Price-List of Reimbursable Medici-
nal Products. 
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The LNHS reimburses only the base price of the medicinal product and only 
certain compensation level of such base price (100%, 90%, 80% or 50%). The 
base price is calculated under the certain formula and in principle is a certain 
part of the lowest retail price of the medicinal product within a certain group 
of products. Accordingly, patients buying a reimbursable medicinal product 
have to make a co-payment for it. 
In general, the selling price of medicinal product in the whole distribution 
chain is not statutory fixed in Lithuania. Wholesale and retail prices are set 
by the wholesalers (distributors) of the medical devices and the retailers (phar-
macies) respectively. However, a certain highest price thresholds which can-
not be exceeded while selling medical devices in the distribution chain (whole-
saler, retailer or final customer/patient) are statutorily set. The MoH approves 
the base, the highest retail prices and the highest wholesale and retail mark-
ups of reimbursable medical devices, and the highest wholesale and retail 
mark-ups of non-reimbursable medical devices. 
 
Quality assurance 
Healthcare service delivery quality assurance: external quality control 
External healthcare quality assurance system consists of: 
a. healthcare institution licensing and control of licensed activity; 
b. healthcare institution accreditation; 
c. healthcare institution certification. 
The following subjects (the Control institutions) are entitled to perform 
healthcare service control:42 
1. Persons appointed by the MoH (when needed); 
2. SHAA is the main institution controlling healthcare service access, 
quality and economic efficiency; 
3. NHIF performs economic control of public funds (amount and quali-
ty) spend on healthcare services; 
4. Lithuanian medicine ethics committee performs control of healthcare 
service ethics; 
5. Public Health Centres under the MOH control public health services 
access, quality and economic efficacy in the regions of Lithuania and 
as a rule also have representations in every municipality. 
Control institutions are entitled to:43 
1. Enter into the healthcare institution premises; 
2. Get required documentation, laboratory tests, patient data, to interview 
staff for the purpose of the inspection; 
3. Require additional tests to be performs on patients; 
4. Request the MoH to withdraw the licence for a healthcare professional 
or for the healthcare institution; 
5. Require that certain healthcare professionals be removed from their 
duties for 1 months to check their professional competences; 
                                                             
42 Art. 52 of the Law on Healthcare Institutions 
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6. Apply sanctions (to warn the institution and to order the rectification 
of the deficiencies; to impose administrative sanctions; to request to 
check professional competences of the healthcare professionals, to sus-
pend all or part of services, to temporally dismiss the managerial bod-
ies of the institutions)44. 
Healthcare professionals and healthcare institutions are both controlled by 
SHAA. This is a mandatory supervision whether statutory licensing conditions 
are obeyed throughout the healthcare delivery. SHAA inspections might be 
scheduled and non-planned. Scheduled inspections45 target medical device 
manufacturers, representatives, importers, distributors and users (healthcare 
institutions using medical devices) as well as healthcare services providers 
(healthcare institutions). Non-planned inspection46 of is performed for differ-
ent causes: the request from the MoH, a complaint that the service quality in 
particular healthcare institution does not meet the prescribed standard, in-
spection whether the deficiencies identified during previous inspection were 
duly rectified; etc. Scheduled and unplanned inspections are free of state fee. 
SHAA performs and publishes annual inpatient healthcare institutions ser-
vice level indicator survey. This survey aims to inform patients about the ser-
vice level in certain institutions. Service level indicators (e.g. patient satis-
faction, antibiotic resistant microbes monitoring level) are approved by the 
MoH47. The 2014 indicator survey is available on the Internet. 
Healthcare institutions may voluntary elect to be accredited by the SHAA48. 
Accreditation is a voluntary initiated evaluation aimed to determine whether 
healthcare institution meets specific set of quality standards.49 So far health-
care accreditation programme is developed only for the primary out-patient 
healthcare institutions in Lithuania.50 These standards were developed as a 
result of EU structural fund project. Accreditation standards are prepared by 
academic institutions in cooperation with healthcare professional associa-
tion.51 Compared to licensing, accreditation has some advantages. First, no 
pressure of sanctions; second, maximum achievable standards are set for ac-
creditation to encourage healthcare institution for continuous development 
(licensing standards are mere safety ensuring minimal mandatory standards).  
So far no accreditations have been performed in Lithuania. 
Certification is a voluntary initiation of healthcare institution assessment ac-
cording to particular standards (e.g. ISO 9000 standards) and formal recog-
nition that these standards are met. Authorised authority which is usually a 
private entity performs certification. 
There is no objective public data gathered to verify the number of certified 
national healthcare institutions. 
                                                             
44 Art. 58 of the Law on Healthcare Institutions 
45 Scheduled inspection order is governed by 3 May 2011 order No T1-390 adopted 
by the head of the SHAA 
46 Unplanned inspection order is governed by 6 February 2013 order No T1-136 
adopted by the head of SHAA 
47 28 November 2012 order No V-1073 of the Ministry of Health 
48 Art. 6 of the Law on Healthcare Institutions 
49 Art. 11 of the Law on Healthcare Institutions 
50 Standard available at: 
http://www.SHAA.gov.lt/files/Istaigu_licencijavimas/Standartas%20LT_visas.pdf  
51 Art. 6(7) of the Law on Healthcare Institutions 
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Healthcare service delivery quality assurance:  
Internal audits of healthcare institutions 
Minimal healthcare quality requirements are approved by the MoH52 and 
cover the following sets of service requirements: patient safety, diagnostic and 
treatment methods and protocols, sound internal audit activities, healthcare 
service quality management and development. Internal healthcare institution 
audit schemes implement and follow these basic MoH approved rules. Also, 
these principles serve as the guidelines for healthcare institution’s independ-
ent service quality development. 
Internal audit is organised by:53 
1. Manager of the healthcare institution in an institution of up to  
5 healthcare professionals; 
2. Appointed employee or outsourced, if the institution holds  
5-50 healthcare professionals; 
3. Internal medical audit group formed under the order of the healthcare 
institution manager, if the institution holds 50-300 healthcare  
professionals; 
4. Internal medical audit department established in the institution 
holding more than 300 healthcare professionals. 
Internal audit functions are the following:54 
1. To engage in determining the healthcare service quality policy,  
aims and quality indicators; 
2. To prepares internal audit procedure; 
3. To deliver annual internal audit report to the manager of the 
healthcare institution and to the department managers; 
4. To perform scheduled and non-planned audits under the direction 
from the manager of the healthcare institution; 
5. To compile an audit plan according to the managers directions; 
6. To organise the registration of side effects and their analyses; 
7. To monitor patient satisfaction within the institution; 
8. To examine patient claims to the extent this falls within its competence; 
9. If assigned by the manager of the healthcare institution, to represent 
the institution towards the Control institutions; 
10. To participate in developing internal documentation related to the 
development of healthcare service quality; 
11. To analyse healthcare service quality improvement. 
The manager of each healthcare institution approves separate internal audit 
procedures: They are not publicly available. Proper documenting of side reac-
tions related to the use of medicinal products, medical devices, blood compo-
nents, hospital infections, x-ray incidents, side effects related to delivery and 
transplant of cells, tissues and organs is regulated by the MoH.55 
                                                             
52 29 April 2008 order No V-338 of the Ministry of Health 
53 Item 13 of the 29 April 2008 order No V-338 of the Ministry of Health 
54 Item 16 of the 29 April 2008 order No V-338 of the Ministry of Health 
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Medical device quality assurance  
SHAA is competent56 to oversee the medical device market from the perspec-
tive of device safety, market delivery and usage. Medical device manufactur-
ers, distributors and importers are subject to the main market delivery re-
quirements control (labelling, etc.). Also, SHAA controls how healthcare insti-
tutions obey the rules on medical device instalment, usage and maintenance.57  
Medical device market control is performed by SHAA through the: 
1. Reception of market data about medical devices used; 
2. Documentation of vigilance data delivered by manufacturer or  
service provider on medical devices; 
3. Application of market safeguard measures (to order withdrawal of 
medical devices from the market, to suspend of to prohibit market 
entry).58 
4. Schedules and non-planned inspections on market players. 
Managers of healthcare institutions are responsible to ensure that medical 
devices are used according to the conditions set by the manufacturer in the 
healthcare institution.59 Manager must appoint a person responsible for the 
following activities in the healthcare institution:60 
1. To record medical device incidents61 and to report them to the SHAA; 
2. To manage a registry of all medical devices that need electric power; 
3. To deliver certain data (i.e. characteristics, utility hours per month, 
number of procedures performed with such a device per months, pur-
chase price, usage costs per moths) about the usage of large scale medi-
cal devices in the healthcare institution. 
 
Medicinal product quality assurance 
Medicinal product quality is ensured through: 
1. Licensing regimes; 
2. Regulatory standards (good practices) for each sector of medicinal 
product distribution chain (pre-clinical investigations; clinical trials; 
manufacturing; distribution; retail sale through pharmacy stores or in-
patient healthcare institutions; medicinal product pharmacovigilance 
reporting); 
3. Scheduled and non-planned SMCA inspections in each part of  
medicinal product distribution chain. 
Manufacturers, distributors and retail pharmacies undergo periodic scheduled 
inspections and non-planned SMCA inspections. Depending on the type of 
activity performed by the inspected entity, SMCA may issue good manufac-
turing practice certificate, good distribution practice certificate or good phar-
macy practice certificate. Failure to eliminate licensing activity infringements  
                                                             
56 Art. 75(2)(5) of the Law on Heath System;  
57 3 May 2010 order No V-383 of the Ministry of Health 
58 Items 61-64 of the 19 January 2009 order No V-18 of the Ministry of Health 
59 Item 11 of the 3 May 2010 order No V-383 of the Ministry of Health 
60 Item 12, 13, 48, 49 of the 3 May 2010 order No V-383 of the Ministry of Health 
61 Defined as a medical device malfunctioning event that could have resulted or can 
result in death or severe injury of the patient 
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identified during the inspection may lead to a temporal suspension or with-
drawal of respective license. Pharmaceutical activity is illegal without a valid 
license. 
If regulatory requirements are infringed with respect to the medicinal product 
(e.g. inappropriate labelling, product safety issues) MA may be suspended or 
withdrawn. 
 
Existing HTA infra-structure 
Private and public healthcare institutions as well as institutions engaging in 
public (societal) health services (e.g. preventive health programmes) are obliged 
to use health interventions (technologies) which are approved for use in Lith-
uania62: It is prohibited to use personal healthcare and public health inter-
ventions (technologies) except for instances prescribed by law63. The MoH is 
obliged64 to set the order for Health Technology Assessment (HTA).  
However, this is a mere legal principle with little further elaboration in law 
and in practice so far. 
HTA institutional structure consists of the HTA Committee (the Committee) 
and institutions performing the HTA (the SHAA, the SMCA and the IoH) 
(the HTA subjects).  
The Committee, established by the MoH in 201465, coordinates and develops 
HTA implementation and application. The Committee is thus a coordinat-
ing body and does not have direct HTA activities among its functions. Sub-
ject performing the actual HTA are the SHAA, the SMCA and the Hygiene 
Institute each in its dedicated field. Both the SHAA and the Hygiene Insti-
tute has so far acquired the EU structural funds for HTA development pro-
jects (2013-2015). Therefore, preparation of HTA procedures is done or un-
der way in these institutions. Also, each of these institutions has published 
information about 3-5 HTAs concluded so far. The SMCA has publicly an-
nounced about its engagement to HTA activities (through EUnetHTA), how-
ever, no further accomplishments seems to have been achieved so far. So far, 
HTA activities seem to develop individually within HTA subjects and over-
all coordination is minimal.  
The Committee activities are governed by the Rules of procedure and the 
Committee Statute.66 Both acts are abstract and very procedural in nature. 
No substantive provisions (e.g. how the Committee interacts with HTA sub-
jects, what are the Committees policy priorities) are included. These legal 
acts are not published so far. MoH intend to do so soon.  
                                                             
62 Art. 45(1)(4) and 50(1)(3) the Law on Healthcare Institutions 
63 Art. 54(1) of the Law on Health System 
64 Art. 54(2) of the Law on Health System 
65 Established by the 21 February 2014 order No V-277 of the Ministry of Health 
66 Both approved by the same 21 February 2014 order No V-277 of the Ministry of 
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The Committee performs the following functions67: 
1. along with HTA subjects determines healthcare technologies that should 
be assessed and delivers a list of such technologies for the MoH; 
2. approves HTA priorities specified by HTA subjects; 
3. examines HTA reports and recommendations delivered by HTA sub-
jects and provides its own recommendation to the Minister of Health; 
4. coordinates HTA subject activities; 
5. along with HTA subjects sets HTA development agenda; 
6. coordinates international HTA initiatives; 
7. engages in HTA awareness raising. 
Although HTA subjects are referred to as institutions (not designated HTA 
bodies within those institutions or their members) in the Committee Statute 
or Rules of Procedure, in practice the Committee coordinates HTA activities 
within the HTA subjects (e.g. the Commission within the SHAA or respec-
tive SHAA officials knowledgeable of HTA and appointed to the Commis-
sion). Committee rights are limited to invitation of external consultants and 
request additional information to perform its functions. Rules of procedure 
state that any data provided to the Committee is confidential. As a conse-
quence, HTA reports are not available for peer reviewing and public use. HTA 
transparency is lacking. 
The MoH assigns Committee the chairperson and its members. Rules of pro-
cedure govern the composition of the Committee. It reserves an undefined 
number of seats for the MoH, single seat remains with every HTA subject 
and two major medical universities in the Committee. However, the compo-
sition may be expanded with representatives of other institutions or agencies. 
Currently, the Committee consist of 19 persons (12 of them are from MoH 
and only 3 represent academia). 
The Committee members are appointed by the MoH and are the following68: 
Table 3.1-5: Members of the HTA-Committee established in 2014 
 Institution Function 
1 MoH Chairperson  
Vice Minister 
2 MoH Deputy chairperson  
Advisor to the MoH 
3 MoH Head of EU Support section  
4 MoH Chancellor 
5 MoH Director of Mother and Child Health Agency  
6 MoH Head of Health Economics Department 
7 MoH Head of Health Care Accessibility and Acceptability Unit 
8 MoH Director Pharmacy Department  
9 MoH Director LNHS Coordination and Healthcare Institution Agency  
10 MoH Head of Legal Department  
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 Institution Function 
11 MoH Director Health Strengthening Agency  
12 MoH Head of Health Strategic Development section  
13 SMCA Director of SMCA 
14 SHAA Head of Medicine Technology Division 
15 NHIF Head of Clinical coding section  
16 Institute of Hygiene Public Health Technology Center/Head of Research and  
Technology Assessment Unit  
17 University Kaunas Lithuanian University of Health Sciences 
Director for Public Health, Research and Education 
18 University Kaunas Kaunas Clinics Hospital, Department of Innovation Assessment  
and Deployment 
Lithuanian Health Sciences University, Faculty of Public Health 
19 Vilnius University Professor Medicine faculty  
 
According to the Statute Committee members are entitled to: 
1. suggest Committee agenda; 
2. examine documentation; 
3. deliver suggestions to the Committee; 
4. voice opinion during the Committee hearings; 
5. vote. 
Committee chairperson: 
1. calls Committee hearings (no further regulation is set as the regularity 
of the hearings, the chairperson seems to be absolutely free when and 
whether to set up a hearing date); 
2. manages the Committee; 
3. leads Committee hearings. 
Committee decisions are adopted following majority vote with chairperson´s 
vote being decisive when other votes are equally split. Members may vote via 
email. 
No regulation is set as to the further use of Committee decision. According 
to unofficial statements from the MoH officials, the Committee decisions are 
provided to the Minister for information and reference only. The ultimate 
decision relating to the health interventions (technologies) is adopted by the 
Minister. Allegedly, this set up intends to ensure the separation of consulta-
tion body (the Committee) and public administration powers (the Minister).  
 
Medical device and related technology HTA 
HTA is theoretically mandatory69 – but not applied in everyday practice – for 
medical devices and related technologies (medical devices and related meth-
ods, methodologies, procedures and interventions used by healthcare profes-
sionals for healthcare service delivery) in situations when: 
1. The cost of medical device related technologies is over 29.000 EUR 
(100.000 LTL); 
2. The medical device related technology is intended to be fully or  
partially acquired from public funds (state or municipal budget, etc.); 
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3. The medical device related technology falls within the following  
priority technologies for HTA assessment: 
3.1. Expensive or new/innovative modification of a current technology; 
3.2. Technology equally effective to a current alternative on the market; 
3.3. Technology capable of significantly reducing sickness rates; 
3.4. Technology capable of being applied to a wide patient scope; 
3.5. Technology applicable to a dependant patient group; 
3.6. Technologies related to implantable medical devices; 
3.7. Technology related to detecting, controlling, treating and  
restoring health disorders. 
SHAA has set the Order for medical device related technology HTA (the Or-
der).70 The Order governs merely procedural aspects of Commission’s activi-
ties and is includes no other matters. To initiate a HTA private entities aim-
ing to sell such technologies must fill in standard form application and attach 
additional studies or HTA analysis performed on the technology in other 
countries. Having received the application, SHAA perform formal examina-
tion of the application within 7 days following the submission and allow (if 
needed) 30 day period for the applicant to rectify identified formal deficien-
cies. If no formal deficiencies are found, SHAA assigns the application to the 
earliest hearing of The Evaluation Commission for Health Technologies Re-
lated to Medical Devices (the Commission). The Commission, established 
back in 2012 by the SHAA, gathers at SHAA premises and includes SHAA 
officials and outside academic and patient organisation experts. The Commis-
sion decides whether particular application falls within the priority and, if 
so, assigns SHAA to perform HTA evaluation and present its recommenda-
tion within 90 days. Indeed currently SHAA has no priority medical device 
technologies approved. All HTA applications are evaluated in chronological 
order. SHAA is currently waiting until the MoH approves priority technolo-
gies for HTA. No public information is available as to what the priority list 
could include.  
The term may be prolonged by 30 days if SHAA finds that additional docu-
mentation is needed. HTA report conducted is delivered to SHAA for review. 
The Commission compiles recommendations based on the HTA report and 
delivers these recommendations to the MoH and to the applicant. The Order 
does not specify whether the HTA report is confidential and remains only for 
further reference of the SHAA or has to be published. SHAA publicly pre-
sents only the abstract of the HTA report. The Commission takes a central 
role in the HTA process related to medical devices, at least in theory. It drives 
medical device HTA policy, directly engages in execution of HTA, and pre-
pares interventions (technology) use and purchase recommendations.  
The Commission consists of 12 persons appointed by the head of SHAA. 
8 members represent medical associations, the rest are representatives of 
SHAA. Commission activities are governed by the Rules of procedure.71 The 
Commission hearing is held upon initiation of the SHAA but no less frequent 
than every half a year. In practice the Commission has not met for a long time. 
Commission members and the SHAA can both form the agenda for the Com-
mission hearing. Chairperson of the Commission may invite outside experts 
to contribute to the Commission hearings.  
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Figure 3.1-2: HTA infrastructure flowchart 
Public health service HTA 
The Institute of Hygiene is in charge of building and developing HTA for 
Public Health interventions. A Research and Technology Unit exists in both 
Public Health Technology Centre (division of the Institute of Hygiene) and 
in the Profession Health Centre (another division of the Institute of Hygiene). 
These units engage in HTAs according to their field competence. A regula-
tion on the procedures for HTA for Public Health interventions has not been 
adopted yet, but is under development. The rules and procedures will likely 
be analogous to the Order adopted by SHAA. The IoH forecasts this for Sep-
tember 2015. HTA for Public Health interventions is supposed to deliver com-
prehensive and scientifically proven data on effective interventions to health 
policy makers and healthcare professionals. The IoH has already performed 
3 HTAs, of which 2 reports are published. 
 
HTA on Medicinal products/drugs 
SMCA is in charge of building and developing HTA for medicinal products. 
Last year SMCA acceded to the EUnetHTA network. A regulation on the pro-
cedures for HTA for drugs has not been adopted yet. SMCA will likely adopt 
the rules and procedures under its order. The rules and procedures will likely 
be analogous to the Order adopted by SHAA. No public information is avail-
able on HTA performed (if any) on drug-interventions. 
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3.2 Analysis of utilization 
of HTA in health care and barriers 
3.2.1 International examples for HTA utilization 
and applications, but also barriers  
Technology assessments are useful to a wide range of decision-makers in 
health care, including government policy makers, insurance companies and 
other payers, planners, administrators, clinicians, patients and industry.  
In a life cycle of health technologies HTA plays a role at different points in 
time and with different methodological approaches. 
 
Figure 3.2-1: The life cycle of health technologies [32] 
The actual utilization of HTA for evidence-informed health policy decisions 
is stimulated by the information need and the according demand of decision-
makers for tailor-made timely HTA-products. The following HTA utilizations 
are prevalent: 
Decisions to in-/exclude new interventions (drugs, procedures, devices) in benefit cata-
logues or positive/negative lists: single technology assessments (STA) are most 
often the methodology of choice. 
Decisions to in-/exclude new interventions (drugs, procedures, devices) in benefit cata-
logues or positive/negative lists: relative effectiveness assessments (REA) give the 
basis for either deciding in favour of one technology or for negotiating (in 
cases of equal benefit-risks) group prices.  
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Decisions on Disinvestment of obsolete or unsafe interventions or such of uncer-
tain benefit (e.g. in the process of the maintenance of the benefit-catalogue 
or positive list): clinicians are often involved for the identification of candi-
dates for disinvestment, followed by STAs or REAs.  
Decisions on procurement of new technologies (e.g. in hospitals, drug or implant 
commissions): available technologies are listed and categorized in groups of 
technologies. Then group assessments are carried out, with special focus on 
add-on services of manufacturer (technical maintenance, training, timely de-
livery etc.). 
Decisions on planning and placement of big devices (e.g. PET) or specialized services 
(e.g. neurosurgery): HTA for planning and placement is based on Health Care 
Needs Assessment (HCNA) incorporating conventional approaches (preva-
lence and incidence data) with quality and outcome data.  
Decisions on quality improvement: HTA gives input to clinical pathways and 
evidence-based (care) guidelines and/or inputs to quality (patient relevant 
outcome) indicators but also to a quality-quantity relations (e.g. in high-risk 
elective surgery).  
Decisions on appropriateness (e.g. in cases of high amount of regional variances 
but equal health outcomes of population): HTA gives input to definition of 
patient groups according to patient characteristics, severity of disease, natu-
ral course of disease, threshold values. 
Decisions on controlled diffusion and coverage with evidence development (e.g. if a 
technology is “promising” but not proven or if the benefit of an intervention 
is uncertain, but the demand/pressure from providers or patients is high): 
HTA supports the generation of (“pragmatic”) evidence under research con-
ditions with inputs to registries and clinical trials (e.g. the definition patient-
relevant of outcomes, instruments to measure them, etc.). 
 
Figure 3.2-2: Common utilizations (need and demand) of HTA 
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Barriers and hindrances in the utilization of HTA  
The gap between HTA research and medical practice or health policy is of-
ten considered as a problem [33]. The timely access to good quality (reliable, 
valid, clear in messages) and relevant HTAs is perceived as a barrier. Other 
barriers are organisational factors such as poor dissemination of HTA, lack of 
material and personnel resources (skills of politicians to understand the need 
and opportunities of evidence and skills of HTA-staff to understand the needs 
and priorities of politicians), staff turnover, but also resistance of professional 
(clinical) bodies or managerial will for a change in the decision-making cul-
ture (from “eminence to evidence”). 
Strategies to increase the use of research evidence are good contacts, collabo-
rations and permanent relationships with health politicians and administra-
tors, but also trust and mutual respect for each other professional needs. To 
increase the utilization and impact of HTA a good understanding of the pro-
cesses, the context and competing priorities as well as the political pressure 
is of advantage [33].  
 
3.2.2 Analysis of perceived need within the 
Lithuanian health system, and barriers  
Needs assessment based on interviews 
“It is better to have a[n HTA] system than to have no system. One can then improve 
an existing system and build capacity [24].” 
The need for a rational system of decision-making on investment and reim-
bursement was apparent to interviewed experts. “Decisions on investments above 
a certain threshold need to be evidence-based [24].” The need for an HTA-function 
within it was also obvious: “The establishment of HTA as an obligatory part of 
informed decision-making is desirable [24].” 
HTA needs at MoH and NHIF 
Decision support is needed in deciding where to allocate limited financial 
resources both at the MoH and at the NHIF, which, in addition, needs to de-
termine at what stage of the life-cycle of a technology to reimburse. “Ideally 
the first step would be to make an HTA [24].” The market for medical devices 
was cited as an example of many similar products with unclear respective ad-
vantages and unclear value for money for the funder. An expectation voiced 
is to learn from an HTA if the technology is appropriate for Lithuania, for 
whom it should specifically be provided and if Lithuania can afford to pay 
for it: “A different kind of analysis than seen in the two HTAs presented at the 
[MoH HTA Committee] so far [24].” Arguments based on clinical effectiveness 
and evidence-based economic arguments are required also to justify decisions 
not to invest and for removing ineffective items from reimbursement lists to 
make financial room for effective innovations. 
Decision support is also required when it comes to determining with which 
measures to best implement strategies and programs. The MoH for example 
needs decision support for implementing the EU funding program 2014-2020, 
with its special focus on public health and investment in evidence-based prac-
tice. Figure 3.2-3 highlights Lithuania’s present primary HTA needs. 
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Figure 3.2-3: Primary HTA needs in Lithuania 
Perceived barriers based on interviews 
When it came to the narrower HTA process, “an indecisiveness about who is in 
charge of HTA in Lithuania [24]” was observed. The importance of putting an 
HTA system in place became very clear from the expert interviews. “Nation-
al HTA should function according to a clear playbook [24].” The independence 
of HTA is widely recognized as a defining feature of an HTA process. Inter-
viewed experts called for the depoliticization of the current HTA regime and 
the addressing of existing conflicts of interest of HTA doers that result from 
their direct or indirect contacts to policy makers. It was noted that compa-
nies applying for the reimbursement of a drug should not be the ones com-
missioning evaluations/HTA of the drug themselves, as is presently the case. 
An HTA function was seen to conflict with a regulatory function if both 
were located at the same institution. 
A body prioritizing HTAs needed for Lithuania was seen as necessary. In ad-
dition to reviewing applications for HTAs from university hospitals, other pro-
viders of health care and from manufacturers, prioritizing should also en-
compass a proactive approach of looking ahead at which health technologies 
would become relevant for the Lithuanian health care system (horizon scan-
ning). In addition prioritizing of HTAs should include existing technologies, 
whose effectiveness is in doubt, as candidates for future disinvestment.  
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Coordination is seen as vital on the demand side for HTAs (MoH, NHIF, 
SMCA, SHAA) as well as among doers of HTA (presently SHAA and IoH). 
HTA doers should cooperate on HTAs with broader topics. The desired HTA 
process should include a clear system of what is to be done with a finished 
HTA report and with the recommendations given based on the report, with a 
clear pathway towards implementation. The scope of HTAs should be broad 
and include public health. HTAs should consider the whole health system 
with its interconnected services. “A new medical device may reduce the need for 
pharmaceuticals [24].” The scope of HTAs should include health system wide 
decisions, like “where to concentrate specialized oncological services or where to 
establish a center of excellence for neurosurgery [24]”. In terms of the currently 
lacking accessibility of completed HTAs and studies on HTA related topics 
done at universities, a system for archiving and retrieving these is proposed. 
In terms of the image of HTA in Lithuania the need for the highest political 
echelon to in the future appreciate the importance of HTA in order for it to 
succeed is highlighted. In addition, decision makers should learn how to in-
terpret the results of HTAs, how to distill the required information from HTA 
reports and how to put this information to use. The quality of HTAs is seen 
as key for its results to be taken seriously by the respective professional com-
munity.  
 
 
3.3 Analysis of HTA institutionalization 
and financing 
3.3.1 International examples for  
HTA institutions and their resources  
Within INAHTA/The International Network of Agencies for Health Technol-
ogy Assessment 55 non-profit organizations with at least 50% public funding 
(which is regarded as an indicator of a considerable stage of institution-
alization [34]) are active members. Within EUnetHTA around 55 HTA in-
stitutions are collaborating. Due to the economic pressure on the health care 
systems, the ever increasing number of products brought to the market by in-
dustry and their extensive marketing activities, as well as demographic de-
velopments, the necessity for making decisions on the efficient use of health 
care resources is growing ever more pressing. HTA is regarded as a means of 
choice to rationally support this process. Today there is hardly an European 
country without one or several HTA institutions, sometimes units in different 
organisational environments. 
Even though HTA is in the process of becoming established and institution-
alized both in individual countries and internationally, the majority (70%) of 
the total number of countries in the European region, and more than a half 
of EU countries do not yet have formalized HTA yet [34]: By “institutionali-
zation of HTA” it is not necessarily meant that a national HTA-institute is 
founded, but that HTA is given a defined role in decision-making.  
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There is not one “best practice” model of HTA-institutionalisation  
in Europe, but many different models: 
 Centralized: IQWIG/Germany, HAS/France, NICE/England, 
SBU/Sweden, ZIN/The Netherlands, NOKC/Norway, etc. 
 (Partly of fully) Decentralized or regionalized: AETS, AETSA,  
AQuAS, AVALIA-T, OSTEBA/Spain;, ASSR, RegVeneto, Reg Emilia 
Romagna and 2 national agencies: AGENAS, AIFA, Italy; etc.  
HTA-coordinated networks with several profiled agencies: SNHTA/Switzer-
land; GÖG, LBI-HTA, DUK/Austria.  
Nevertheless, the majority (around 80%) in EUnetHTA is publicly funded 
and closely associated with the government/ministry/health insurances: 
42,5% are governmental agencies, 5% agencies within a compulsory (public) 
health care insurance, 32,5% are academic institutions [34]. And, since po-
litical investment and reimbursement decisions happen (often) under pres-
sure from powerful professional groups (clinicians, industry), the independ-
ence of HTA is regulated in most countries. The guiding principles repre-
senting the basis of the working procedures of the HTA institutes are very 
uniformly defined by the cornerstones of “independent, objective and evi-
dence-based, transparent scientific validity”.  
Since HTA is one component of a broader health-care decision-making pro-
cess that can best be described as a synergistic work-division between health 
policy, approval and reimbursement and HTA. Each component is defined 
and determined by distinctive functions and roles. HTA as the scientific part 
in the chain is characterized by critical appraisal and systematic synthesis of 
the available evidence. Summarized in the slogan “globalising evidence and 
localizing the decision” eventually recommendations are given, a decision is 
made. The independence from interest-groups and their influence as well as 
from political interference is an essential prerequisite for objective HTA-in-
formation. The independence, thus, is manifested within an agreed framework 
which is “based on the principle of good governance including transparency, 
objectivity, independence of expertise, fairness of procedure and appropriate 
stakeholder consultations” [2]. At the same time HTA needs to stay in arm´s 
length to health policy for providing relevant and timely answers to policy 
questions.  
This repeatedly stressed independence from financiers and contracting 
agencies attempts to be reached through various mechanisms: 
 Detailed Process and task descriptions 
 Establishment of bodies and committees to monitor the  
scientific quality 
 National and international Peer-Reviewing of all products 
 Decoupling of recommendation (assessment, appraisal) and decision. 
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At the same time – the EU is a common market – the high degree of redun-
dancy in the processing of particular HTA issues is increasingly becoming 
more obvious. In the EUnetHTA “Planned and Ongoing Projects/POP-data-
base” [35], a complete overlapping (same theme at the same point in time) in 
10-12% of the HTAs (primarily in the assessment of new medicines and new 
procedures/devices after market entry, but before reimbursement) has become 
apparent. 30% of the HTAs address similar issues, such as disease patterns 
(e.g., depression, AIDS, dementia, rehab, etc.). The European network accord-
ingly aims for a closer cooperation. With an increasing Europeanisation of 
HTA, it is essential to share global knowledge and to embed it into national 
system knowledge. In this way, the communication and coordination effort 
rises in favour of labour distribution and (hopefully) lowers the redundancy.  
Naturally, small countries have less capacities (resources) for comprehensive 
national HTA of critical numbers and therefore devote more time to interna-
tional collaborations.  
Scandinavian countries, measured in terms of their population figures, invest 
comparatively much in HTA institutes involved in health care administra-
tion: EUR 8.85mio in Sweden/SBU (pop. 9.7mio), or EUR 3.7mio in Norway/ 
NOKC (pop. 4.9mio), or 1.3mio in Finland/FinOHTA at THL (pop 5.4mio). 
The Mediterranean countries of Italy and Spain are characterised by many 
regional institutions and in part with distinctive profiles (only HTA for hos-
pitals, only HTA for technologies/medicines after market entry, only horizon 
scanning). Resource deployment in two (small) Spanish is:  
 Basque Country/OSTEBA € 2.4mio (pop. 2.1mio) – 14 FTE  
(20 ongoing projects) 
 Galicia/AVALIA-T € 0.64mio (pop. 2.1mio) – 5 FTE  
(12 ongoing projects) 
In larger countries (Germany: pop. 82mio) IQWiG has considerable more fi-
nancial resources (EUR 13m). 
At the LBI-HTA (1,1mio budget, 8.3mio pop) with 14 FTE around 1 compre-
hensive HTA (6 months) + 1-2 rapid (STA, 2-3 months) can be produced by 
each of them 11 researchers. This is strongly dependent on additional activi-
ties (scientific publishing, dissemination activities, teaching, administration). 
The process of institutionalising a national HTA programme is a synthesis of 
top-down and bottom-up activities and relies on strong networking activities. 
The (human) resources invested in national HTA institutions or networks 
show a wide range, strongly depending on the mandate agenda (only HTA for 
drugs/devices or also comprehensive HTA or health services research, guide-
line development, horizon scanning).  
 
 
changing conditions for 
HTA institutes: 
reduction of 
redundancies, 
supranational division  
of labor 
 
Europeanisation: 
embedding global 
evidence into national 
system knowledge 
Scandinavian countries 
comparable to size of 
country: large 
investments in HTA 
 
decentralized/regional 
Spanish HTA  
(pop 2.1 million):  
640.000 to 2.4 m. 
Germany:  
IQWiG € 13m 
LBI-HTA:  
1 comprehensive +  
1,5 rapid HTA p.a. per 
researcher 
“good practice” 
examples for 
institutionalisation of 
HTA and impact on 
health policy 
  
B
ackgro
u
n
d
 an
alyses fo
r H
T
A
 Strateg
y 
LB
I-H
T
A
 | 20
15 
53 
Table 3.3-1: Annual Budgets and FTE/Full Time Equivalents of European INAHTA-Members  
HTA Institution 
EUROPE country 
Resources for  
HTA in EUR 
Pop served 
in Mio FTE URL 
AETS – Agencia de Evaluación de Tecnologias Sanitarias Madrid, Spain 746.000,00 0.04 15 http://www.eng.isciii.es/ISCIII/es/contenidos/ 
OSTEBA – Basque Office for HTA Vitoria-Gasteiz, Spain 2.607.000,00 2.1 14 http://www.osanet.euskadi.net/osteba/en 
KCE – Belgian Federal Health Care Knowledge Centre Brussels, Belgium 10.244.000,00 10.6 45 http://kce.fgov.be 
NOKC – Norwegian Knowledge Centre for the Health 
Services 
Oslo, Norway 3.725.000,00 4.9 50 http://www.nokc.no 
SBU – Swedish Council on HTA in Health Care Stockholm, Sweden 8.847.000,00 9.7 60 http://www.sbu.se 
NETSCC, HTA – NIHR Coordinating Centre for HTA Southampton, UK 184.272.000  
(all NETSCC managed 
programmes) 
64 200 http://www.hta.ac.uk 
ZIN – Zorginstituut Nederland Diemen, the Netherlands 9.591.000,00 16 4 http://www.zorginstituutnederland.nl/ 
ASSR – Agenzia Sanitaria e Sociale Regionale (Regional 
Agency for Health and Social Care) 
Bologna, Italy 372.000,00 4.5 5 http://asr.regione.emilia-romagna.it/asr/index.htm 
AQuAS – Agència de Qualitat i Avaluació Sanitàries de 
Catalunya 
Barcelona, Spain 2.235.000,00 7 54 http://aquas.gencat.cat 
HIQA – Health Information and Quality Authority Dublin, Ireland 1.397.000,00 4.5 7 http://www.hiqa.ie 
THL/FinOHTA – Finnish Office for HTA Helsinki, Finland 1.303.000,00 5.4 27 http://www.thl.fi/finohta 
AVALIA-T – Galician Agency for HTA Santiago de Compostela, 
Spain 
652.000,00 2.7 5 http://avalia-t.sergas.es 
AETSA – Andalusian Agency for Health Technology 
Assessment 
Sevilla, Spain 839.000,00 7.5 23 http://www.juntadeandalucia.es/salud/servicios/ 
aetsa/ 
HIS – Healthcare Improvement Scotland Glasgow, Scotland, UK 652.000,00 5.1 12 http://www.healthcareimprovementscotland.org 
GÖG – Gesundheit Österreich GmbH Vienna, Austria 392.000,00 8.4 6 http://www.goeg.at 
LBI-HTA – Ludwig Boltzmann Institut HTA Vienna, Austria 1.398.000,00 1.1 14 http://hta.lbg.ac.at 
Age.na.s – The Agency for Regional Healthcare Rome, Italy 4.977.000,00 60 50 http://www.agenas.it  
AOTMiT – Agency for Health Technology Assessment 
and Tariff System 
Warsaw, Poland 3.354.000,00 38.2 40 http://www.aotm.gov.pl 
CEM – Inspection générale de la sécurité sociale (IGSS), 
Cellule d’expertise médicale 
Luxembourg, 
Luxembourg 
x x x http://www.mss.public.lu/acteurs/igss/cem/ 
index.html 
CEDIT – Comité d´Evaluation et de Diffusion des 
Innovations Technologiques 
Paris, France x 12 5 http://cedit.aphp.fr 
HAS – Haute Autorité de Santé Paris, France 931.000,00 65 17 http://www.has-sante.fr 
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HTA Institution 
EUROPE country 
Resources for  
HTA in EUR 
Pop served 
in Mio FTE URL 
DAHTA @DIMDI – German Agency for HTA at the 
German Institute for Medical Documentation and 
Information 
Cologne, Germany 777.000,00 80 11 http://www.dimdi.de 
CRD – Centre for Reviews and Dissemination York, UK 4.004.000,00 55 56 http://www.york.ac.uk/inst/crd/ 
SHAA – State Health Care Accreditation Agency under 
the Ministry of Health of the Republic of Lithuania 
Vilnius, Lithuania not separated from 
main SHAA budget 
3 7 http://www.SHAA.gov.lt 
IQWiG – Institut für Qualität und Wirtschaftlichkeit  
im Gesundheitswesen 
Cologne, Germany 13.000.000 82 x http://www.iqwig.de 
MTU-SFOPH – Medical Technology Unit – Swiss 
Federal Office of Public Health 
Bern, Switzerland x 8.0 6 http://www.snhta.ch 
UVT – HTA Unit in A. Gemelli Teaching Hospital Rome, Italy x 58 10 http://www.policlinicogemelli.it/area/?s=206 
HTA-HSR/DHTA – HTA & Health Services Research Århus, Denmark 745.000,00 5.5 9 http://www.mtv.rm.dk 
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3.3.2 Analysis of existing HTA resources in the 
Lithuanian health system  
Lithuanian HTA is currently chiefly carried out by two institutions, both 
under the MoH, with defined content areas. Both institutions (SHAA, IoH) 
benefit from EU funded projects: 
 State Health Care Accreditation Agency (SHAA) for medical devices 
 Institute of Hygiene (IoH) for Public Health and  
 possibly in the future State Medicines Control Agency SMCA for 
pharmaceuticals: SMCA is applying for EU structural funding in 2016 
A small hospital-based HTA unit has been established at Kaunas university 
hospital. 
 
Mapping resources: estimation of FTE already working in HTA 
SHAA’s Medical Technology Section with a staff of 7, works on HTA. 5 em-
ployees work on doing HTAs full time. The individual authors of SHAA HTA 
reports are not disclosed. So far SHAA completed 6 HTAs and is currently 
working on 4 topics. The topics for the HTAs on medical devices either come 
from manufacturers, that can apply for an HTA at SHAA, or from the MoH 
or from the National Cancer Institute. 
According to the publicly available information on 2 July 2015,  
SHAA completed and published abstracts of 6 HTAs: 
1. “Assessment of breast tomosysthesis diagnostic efficacy in  
diagnosing breast cancer”; 
2. “Assessment of breast ultrasound scan diagnostic efficacy in  
diagnosing breast cancer”; 
3. “Assessment of duplex flow radioabsorbtiometrix and quantitative 
computer tomography methods in diagnosing osteoporosis”; 
4. “Cochlear implant efficacy to cure adult and children deafness”; 
5. “Treatment of surgical type 2 diabetes: assessment of stomach  
surgeries”; 
6. “Surgical treatment of urinary incontinence: assessment of  
implantation surgery of artificial sphincter for men“. 
Only the summaries of the conducted HTAs are publicly available on SHAA 
website: http://www.vaspvt.gov.lt/node/486. 
Judged on the published summaries the HTA reports include the following 
sections: reasoning the HTA need; methods used; the review of the assessment 
(focusing on the pricing and life quality statistics); conclusions (on life quality 
statistics and complications); assessment of limitations to conclusions (e.g. 
scarcity of source materials); recommendations (as to whether and when to 
apply the technology; the impact of the technology on life quality, public ex-
penses). 
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The IoH is responsible for HTA in public health, presently has a staff of 12 
involved in HTA, 8 of them doing HTA full-time. HTA staff is active in two 
separate, but cooperating Centers at the IoH: Occupational Health and Public 
Health. So far the IoH has completed 3 HTAs (2 published). The topics were 
prioritized internally through a Delphi process with stakeholders, and also 
suggested by the MoH.The IoH is in the process of building HTA procedures 
for its further activities. Summaries of the 2 HTA reports are published: 
1. “Screening and short intervention for prevention of alcohol misuse” 
(see http://technologijos.hi.lt/uploads/pdf/Alkoholis%20_ 
santrauka_viesinimui.pdf); 
2. “Effectiveness of Physical Activity Interventions in the Workplace” 
(see http://technologijos.hi.lt/uploads/pdf/FA%20_ 
santrauka_viesinimui.pdf). 
3. “Effectiveness of interventions to promote physical activity among 
adults and practice of interventions in Lithuania” (unpublished). 
Published summaries refer to HTAs performed under the EU structural funds 
framework. The third completed HTA (unpublished) is entitled  
At present the IoH is working on two further HTA projects:  
1. “Telephone counselling for smoking cessation”. 
Currently there are no HTA activities at the SMCA. No public information 
is available as to what extent SMCA staff is planned to be involved in HTA 
activities in the future. 
In 2014 the first Lithuanian hospital-based HTA unit was established at Kau-
nas University Hospital and staffed with half a full-time equivalent position 
supported by a Masters student. The unit serves to present the HTA-evalua-
tions to the clinic administration for the decision making whether to acquire 
new technologies. 
There are also some HTA related activities at Medical Associations that pre-
pare guidelines.  
In 2014 a HTA Committee was established at the MoH (see details in 3.1.2.2.) 
The composition of the Committee with high level MoH representatives sug-
gest that the Committee is designed to decision making on a rather strategic 
level. In fact, the most of MoH representatives within the Committee have 
minor involvement in HTA activities outside the Committee.  
A number of private entities exist that declare an involvement in HTA. These 
are mostly single consultants offering marketing authorisation acquisition and 
maintenance, assistance in enrolling medicinal products into reimbursement 
schemes, medicinal product risk benefit ratio assessments for pharmaceuti-
cal companies. 
To our knowledge medicinal product pharmaco-economic assessment is of-
fered by the following companies: UAB “Diavera”, UAB “Farmanis”, UAB 
“Maras”. 
The Lithuanian capacity for academic HTA research is located at 3 universities: 
1. Lithuanian university of health sciences (LUHS),  
Kaunas (health economics and HTA) 
2. Mykolas Romeris University, Vilnius (health system and health policy) 
3. Vilnius University (VU), Vilnius (public health, epidemiology,  
health statistics, HTA) 
resources at Institute  
of Hygiene IoH:  
8 full-time HTA doers 
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resources at SMCA: 
unclear, likely none 
resources at  
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University Hospital 
resources at MoH:  
HTA Committee 
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Evidence based medicine movement and HTA 
Active promotion of evidence-based medicine has started in 2013 when two 
medical students from Oxford University organized an Evidence based med-
icine conference and invited internationally recognised speakers. The second 
Evidence based medicine conference was organized in Kaunas in partnership 
with lecturers from Lithuanian university of health sciences in 2014. The tar-
get audiences of the conference are students, residents, PhD students and 
young doctors. It is planned to organize a third Evidence based medicine con-
ference in autumn 2015. 
In summer 2014, virtual evidence based medicine centre was established at 
the Clinic of Internal Medicine, Family Medicine and Oncology in accord-
ance with decision of the Faculty of medicine council of Vilnius University. 
The aim of the Virtual evidence based medicine centre is to improve health 
care, by disseminating the highest grade clinical evidence and developing 
skills in finding evidence, critical appraisal and properly adapt to their pa-
tients. Virtual evidence based medicine centre may serve as a partner to the 
SHAA and IoH to promote HTA to professional community. 
 
Role of Physicians:  
Evidence Based Medicine Guidelines and Clinical Pathways 
There is no single coordinating institution for development and implemen-
tation of clinical guidelines and diagnostic and treatment pathways. Although 
42 clinical methodologies (guidelines) are presented on the MoH website at 
present, only few of them are prepared in accordance with Agree II criteria 
for quality and reporting of practice guidelines. Short recommendations for 
preparation and implementation of diagnostic and treatment methodologies 
(guidelines) and descriptions of procedures were approved by the MoH in 
May 200672. This document sets basic requirements for guideline structure, 
coordination and publication, however, it is insufficient to develop a quality 
document. 
Two high value projects on clinical guidance and diagnostic and treatment 
pathways development were launched in 2013. 
As a part of Lithuanian – Swiss Cooperation Programme funded project “Im-
provement of perinatal and neonatal health care services in Lithuania“, 70 ev-
idence based clinical guidelines (30 in neonatology and 40 in obstetric) were 
developed in 2014. Each guideline was prepared by the multidisciplinary 
team of physicians from Vilnius, Kaunas, Siauliai and Marijampole hospi-
tals, and comprises 5 components: description of methodology, description 
of procedures, implementation inventory, audit inventory and information 
for the general public.  
                                                             
72 Description of procedures for drafting and implementation of diagnostic and treat-
ment methodologies approved by 17 May 2006 order No V-395 of the Ministry of 
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In 2014-2015 within the EU structural funds project UAB EVP group has de-
veloped 123 pilot diagnostic and treatment protocols (pathways) in the fields 
of cardiology, traumatology, neurology, paediatric and oncology73. Each path-
way was drafted in the group of experts led by expert physician with a scien-
tific degree, following a standardised drafting and implementation algorithm. 
All protocols were developed following the new MoH Order for preparation, 
review and renewal of diagnostic and treatment protocols74 requiring each 
protocol to cover only one disease, syndrome, condition or procedure and to 
be revised at least once every three years by health care institutions.  
 
 
3.4 Analysis of human resources and 
capacity building 
3.4.1 International examples of human resources 
in HTA and capacity building for “emerging” 
countries  
Even though a formal HTA programme might not be in place in some coun-
tries, decision-making about the adoption of new technologies is part of the 
operational routine of health authorities and health service providers. Such 
decisions are frequently based on unilateral industry information or single 
experts. The challenge is to change the decision-making culture towards evi-
dence-based decisions. This change requires – beside the firm commitment 
from health policy (health authorities) – sufficient national capacities to carry 
out HTA [34]. 
Therefore the concept of capacity building encompasses  
 not only the training of HTA core staff,  
 but also the involvement of existing (relevant) capacities in other ac-
ademic institutions (universities), and  
 also the sensitization of key stakeholders.  
 
Human resources in European HTA Agencies 
The diversity of the subjects within Health Technology Assessment requires 
a broad range of different competences in human resources: content-wise 
and methodologically. HTA is by definition multi-disciplinary: the availa-
bility and recruiting of trained staff is considered a scare resource and an 
important barrier even in countries with long-standing HTA tradition [34].  
 
                                                             
73 Diagnostic and treatment protocols (project). Ministry of Health. Retrieved July 1, 
2015, from http://www.sam.lt/go.php/lit/Diagnostikos-ir-gydymo-protokolai-
Projektas 
74 Order for preparation, review and renewal of diagnostic and treatment protocols 
approved by the 2 December 2014 order No V-1248 of the Ministry of Health 
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Staff in HTA comprise researcher from different fields: 
 Staff at HTA-institutions: information-specialist, specialists in medi-
cine, biology, pharmacology, genetics, epidemiology, economics, psy-
chology, communication, public health, nursing, social science, com-
munication etc. 
 External staff: clinical specialists, statistics, modelling etc. 
The required number of human resources is highly dependent on the man-
date of the HTA agency. Covering the full range of human resources is not 
always possible, therefore a strong network of external collaborating experts 
in specialized fields of medicine and/or methodology is a pragmatic and flexi-
ble solution for many HTA institutions. Considering this option of “outsourc-
ing” resources for commissioning must be available and the training of HTA 
skills for the collaborating experts must be considered (and arranged). 
To also involve the external experts in HTA training can be considered as 
part of growing fundament for the culture of evidence-based health care. 
 
Capacity Building: Training to conduct HTA 
Owing to the multi-disciplinarity of HTA, human resources must be adequate-
ly trained in order to cope effectively with the wide range of possible HTA-
topics. Besides the basic academic education in the respective discipline of 
the researcher, training in HTA specific methodologies is required: 
 Systematic literature searches in different databases, documentation of 
the search-strategy, administration and handling of literature selection, 
retrieval, documentation in PRISMA, citation, etc.  
 Quality assessment and critical appraisal of clinical studies with estab-
lished assessment instruments, knowledge of, assessing and avoiding of 
biases, etc. 
 Extracting data and synthesizing the evidence (qualitative,  
quantitative/meta-analysis, decision-analysis etc.) 
 Arriving at and formulating recommendations with established  
instruments (GRADE). 
 Writing and publishing the results for different target audiences. 
 
Capacity Building:  
Training to understand and implement HTA findings 
The communication with the decision-makers is of essential importance for 
the actual utilization and implementation of HTA findings. Presentations 
for policy and decision-maker must encompass 
 Possible utilizations of HTA customized to the audience 
 Projects that proof the concept (impact on savings or on risk reduction) 
 Some examples showing the difference in outcome between biased/ 
selective and evidence-based research findings 
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Networking, “partnering” and collaboration 
Since esp. small countries can never have the capacities (such as NICE/UK) 
to assess all new technologies and interventions before their introduction, or 
for other HTA utilizations,  
 skills to use others´ assessments in the national context and  
 relations for collaborative assessments  
are essential also for national efficiency.  
Strong external networks with institutional partners and within HTA-
networks (EUnetHTA, INAHTA) are of utmost importance, but need time 
and resources to establish and to foster to create a working environment of 
mutual trust. With the increasing Europeanisation due to EUnetHTA the 
exchange of staff for a certain period is one concept to learn from estab-
lished institutions or on processes elsewhere. 
 
3.4.2 Analysis of existing training  
in HTA and capacity building in Lithuania  
Mapping the landscape of advanced training/ 
capacity building for HTA staff  
Continuing professional education for doctors, nurses and pharmacists in 
Lithuania, as well as in other Eastern and Central European countries (except 
for Estonia) is mandatory. Within five years, physicians and pharmacists75 
must to devote at least 120 hours and nurses – at least 60 hours76 for profes-
sional development. Continuing education for public health professionals is 
neither compulsory nor regulated. 
Various professional development forms are legitimate in Lithuania: courses, 
internships, lectures, presentations, publications in peer reviewed journals 
and their annual subscriptions, scientific conferences, seminars, international 
congresses, studies. Distance learning is also available for continuing medical 
education. 1 credit hour of continuing medical education course in Lithua-
nian educational institutions equals to 1 academic hour (45 min.), whereas 1 
academic hour spent in international scientific congress or conference (both 
in Lithuania or other country) is equated to 1.5 credit hours. In accordance 
with European Accreditation Council for Continuous Medical Education 
(EACCME) rules, no more than 3 CME credits are awarded for a half-day 
course and 6 CME credits a for a full-day course. Course duration is not re-
stricted in Lithuania. 
Only institutions that provide training programmes (conferences, lectures, 
courses, etc.) approved by the Ministry of Health are eligible to issue the 
mandatory CME credits. Training programs in fields of personal health and 
pharmaceuticals are administered by the Training and Specialization Centre 
for Nursing Personnel. The Centre for Health Promotion and Disease Pre-
                                                             
75 Procedure on improvement and financing of professional qualification of health 
care specialists and pharmacists approved by 18 April 2002 order No 132 of the 
Ministry of Health. 
76 Description of procedures for authorisation and renewal of nursing licences and 
certificates approved by 1 November 2001 order No V-512 of the Ministry of Health 
(updated by 29 June 2001, order No V-549).  
national HTA efficiency 
relies on HTA transfer 
from other countries + 
on collaborations  
strong external 
networks and 
collaborations 
continuing medical 
education (CME) 
mandatory for doctors, 
nurses, pharmacists 
 
CME for public health 
professionals neither 
compulsory nor 
regulated 
universities or 
institutions approved by 
MoH can issue CME 
credits 
Background analyses for HTA Strategy 
LBI-HTA | 2015 61 
vention administers public health programmes. Training programmes devel-
oped by specialized universities and colleges as well as hospitals of Vilnius 
university and Lithuanian university of health sciences do not need an ap-
proval from the Ministry of Health. 
Health professionals are also able to obtain mandatory CME credits from 
formal educational institutions in the EU member states, Switzerland or the 
EEA states. 
CME courses of Vilnius university and Lithuanian university of health sci-
ences are administered through the information system entitled MEDAS 
(www.medas.lt). Educational programs of other institutions are administered 
through NHIF information system SVEIDRA subsystem METAS   
(http://kvp.vlk.lt/METAS/). 
The mandatory continuing education system of Lithuania is not favourable 
to the application of HTA principles in the country. Training in the field that 
is not obligatory for the participant (e.g. a physician takes a course in phar-
macy, economics, information technology, finance, management, social work, 
sociology, statistics, law etc.) is awarded with only 1/3 CME credit hour per 
hour of training. At present, there is no programme for HTA, although sys-
tem of formal continuing education offers several courses related to this as-
sessment.  
We have searched METAS and MEDAS databases trying to retrieve courses 
in health care management, hospital management, public health and health 
services, epidemiology, medical statistics, health economics and evidence 
based medicine. Table 3.4-1 below summarizes the results. 
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Table 3.4-1: List of continuing medical education courses attributed to HTA in Lithuania 
Subject 
Vilnius University Lithuanian university of health sciences Other providers 
N Title/Provider/Target audience N Title/Provider/Target audience N Title/Provider/Target audience 
Public Health 0  1 Public Health Surveillance/Department of 
Health Management/Public health 
professionals 
6 1. Public Health Surveillance/Institute of Hygiene/ 
Public health professionals;  
2. Health Impact Assessment (3 programmes)/ 
Centre for Health Promotion and Disease 
Prevention/Public health professionals; 
3. Development and implementation of public 
health programmes/Centre for Health Promotion 
and Disease Prevention/Public health 
professionals;  
4. The modern concept of public health/Centre for 
Health Promotion and Disease Prevention/Public 
health professionals  
Health care 
management/
Hospital 
management 
4 1. Management of medical services/Clinics  
of Internal medicine, Family medicine and 
Oncology/Physicians 
2. Quality management of health care 
laboratories/Department of physiology, 
biochemistry and laboratory medicine/ 
Department Physicians, biologists 
3. Methods for biochemical testing and 
quality management/Department of 
physiology, biochemistry and laboratory 
medicine/Physicians, biologists 
4. Health care management innovations in 
public health/Public health institute/Public 
health professionals 
5 1. Quality management in health care/ 
Department of Health Management/ 
Physicians 
2. Teamwork and case management in 
outpatient mental health care 
system/Institute for behavioural 
medicine/various 
3. Basics of management and health 
economics/Department of Health 
Management/Public health professionals 
4. Health care Management/Department of 
Health Management/Nurses 
5. Assurance of nursing quality/Department 
for nursing and care/Nurses 
7 1. Development of the system for monitoring of 
qualitative and quantitative indicators of for 
health care services providers/VsI Safety and 
quality experts Bureau/Physicians, nurses 
2. Development and implementation of process for 
medical devices management for in health care 
institutions/VsI Safety and quality experts 
Bureau/Physicians, nurses  
3. Development of the internal quality system and 
audit documentation in health care institution/ 
VsI Safety and quality experts Bureau/ 
Physicians, nurses  
4. Patient services quality management in health 
care institution (3 programmes)/UAB Centre for 
Human Studies/Physicians, nurses  
5. Systematic management of the personnel of 
health care institution)/UAB Centre for Human 
Studies/Physicians, nurses 
Basics of management and economics/Centre for 
Health Promotion and Disease Prevention/Public 
health professionals 
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Subject 
Vilnius University Lithuanian university of health sciences Other providers 
N Title/Provider/Target audience N Title/Provider/Target audience N Title/Provider/Target audience 
Epidemiology 1 Epidemiological research planning and  
data analysis/Public health institute/ 
Epidemiologists 
0  0  
Medical 
statistics 
1 Basic statistics for inequalities assessment/ 
Public health institute/Public health 
professionals 
1 Health statistics/Department of preventive 
medicine/Physicians 
0  
Evidence based 
medicine/ 
Health 
economics 
0  2 1. Evidence-based intensive care and 
economic evaluation/Intensive care 
clinic/Physicians 
2. New paradigm for nursing development: 
from evidences to actions/Department for 
nursing and care/Nurses 
0  
 
 
Background Analysis for National HTA Strategy for Lithuania 
64 LBI-HTA | 2015 
In total 28 CME programmes were identified. Almost half of the programmes 
were in the field of health care or hospital management and most of them 
were offered for physicians and nurses training. 
Governmental public health institutions (Hygiene Institute, Centre for Health 
Promotion and Disease Prevention) and universities focus their trainings on 
specialty groups (e.g. public health professionals, physicians), while private 
entities offer services for combined target groups (courses for both – physi-
cians and nurses). 
 
3.5 Analysis in HTA processes and products, 
special focus assessment of medical devices 
3.5.1 Generic “good practice” in HTA processes 
and products 
The “knowledge value chain” in the healthcare sector is helpful to position 
HTA in the wider field. The knowledge value chain spans from basic research 
on through the domains covered by HTA (synthesis, assessment, appraisal), 
then to the health policy field of decision making until the phases of dissem-
ination and finally implementation (utilization) in practice (see Figure 3.5-1) 
and monitoring of effects and impact. These steps however are not distinct 
from each other: There will often be interaction between the steps of assess-
ment, appraisal and decision-making, e.g. through the initial health policy 
influence on choosing the question an HTA should answer. 
 
Figure 3.5-1: Knowledge value chain in the health sector. Source: developed from [36] 
HTA as a research-based and user-oriented assessment of relevant available 
knowledge has (see Figure 3.5-1) a bridge function between the domains of 
research and policy decision-making. HTA does not make complexity disap-
pear but offers a structure for taking multifaceted decisions. After it is clari-
fied that a certain policy question raised at the outset is suitable for an HTA, 
an HTA question is derived. In the actual research phase of HTA, best avail-
able evidence from various areas and perspectives is brought into the thorough 
analysis and assessment. Since HTAs have consequences on health policy 
decisions on procurement, reimbursement and planning it is of utmost im-
portance that the process and the products of HTA are transparent and trace-
able: the systematic approach to searching, to extracting and to summarizing 
data and the disclosure of all methods make the results open to scrutiny.  
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This is especially important in circumstances of criticism or conflict with 
stakeholders (clinicians, manufacturer, patients). 
Several national handbooks and HTA-methods guidelines present the phases 
of HTA: Denmark [37], England [38], Austria [39]. NICE [38] has a special 
focus on involvement and participation of stakeholders including independ-
ent academic groups, manufacturers and sponsors, patient and carer groups, 
healthcare providers and commissioners of health services, clinical specialists, 
commissioning experts and patient experts. Even if “good practice” standards 
are established for HTA decisions on the adaption to the national context of 
the process is necessary. Decisions have to be made. 
It is essential to know (not to forget) that HTA has most impact if associated 
(bound to) actual health policy decision to be taken. 
 
The accepted characteristics of HTA (clear formulation of the problem, explic-
it methodology, a wide view on the technology beyond safety and effectiveness) 
[40] are illustrated in greater detail in the HTA assessment process towards 
best practice of Figure 3.5-2 below. An HTA is initiated either through the 
identification of an assessment need (system-perspective of HTA need) or 
through the submission of an assessment request (applicant´s initiative of 
HTA need). In most health care systems both options for HTA topic genera-
tion take place, since leaving the HTA-agenda only to submission-driven tech-
nology assessments would mean to limit the HTA spectrum to products ra-
ther than to processes/procedures or human resources-intensive interventions. 
Options to decide are: 
 Submission-based assessments (of pharma or device products): the submis-
sion constitutes the basis for assessment (Model BAG/Switzerland: 
Applicant has to deliver full HTA, HTA-agency “controls” only ap-
plication). 
 Procedure-based assessments: not single devices, but the intervention in 
a specific indication (with ev. different devices) is issue of the HTA 
(Model IQWIG/Germany). 
 Comparative effectiveness HTA: all comparators (also watchful waiting) 
are considered (Model: AHRQ/USA).  
 Relative effectiveness HTA: the technology (device, drug) in question is 
compared to competing technologies (devices, drugs). 
 Research-initiated HTAs 
 Public or expert consultation on needs for HTA 
 Etc. 
Due to the fact that HTA resources have to be used as efficiently as health 
care resources, priorities on commissioning have to be set [41]. Prioritisation 
can be carried out in a number of ways depending on resources and time 
available, transparency of process and who is involved. Rarely it will be pos-
sible to assess all new and some old interventions. In general HTA resources 
will be used for “high volume and high costs interventions with a high amount 
of uncertainties”. To use explicit criteria might be of help under political 
pressure. 
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Options to decide are:  
 Formal priority setting process [42] based on criteria (e.g. [43])  
for deciding committee.  
 Informal, discussion- and consensus based process on HTA  
necessities deciding committee.  
 Public or expert consultation on priorization. 
The demand for HTAs is subsequently prioritized and an HTA on a particu-
lar health technology is commissioned. 
In the next step the policy questions are defined and the HTA protocol is 
elaborated. The policy question reflects the context in which the assessment 
is carried out [44]:  
 Who initiated the report? Who commissioned it? (policy-maker, health 
care manager/administration, 3rd party/manufacturer, patients´ advo-
cate, HTA-institution). 
 Why is an assessment needed right now? (new technology, new indi-
cation, structural/organizational changes, safety/ethical concerns, old 
technology etc.). 
 Which decision is the assessment going to support? (investment deci-
sion, market approval, planning, in-/exclusion benefit catalogue, plan-
ning of capacities, guidance on best practice, investment in research, 
organization of service provision). 
 Who represents the primary target audience for the report? (political de-
cision-makers, 3rd parties/manufacturer, hospital managers, clinicians). 
In this so called “scoping” phase of developing a research questions feasible 
to answer the policy question (translation), background materials for orien-
tation and for determination of (development and diffusion) status the tech-
nology are gathered. Options for “scoping” are: 
 Meeting with experts (e.g. clinicians in the respective medical field) 
in order to understand e.g. comparators, organizational and infra-struc-
tural needs and other influential factors etc. 
 Development of HTA-protocol based on published materials. Obtain-
ing of written feedback by experts (via mail). 
 Even public consultation of HTA project-protocol is possible [45] (Mod-
el IQWIG/Germany; KCE/Belgium: Patient involvement for defini-
tion of critical endpoints). 
In order to give an evidence-based answer to the problem outlined in the poli-
cy question, formulating the actual research question is a crucial part in the 
process. Based on this “scoping” process an HTA protocol has to be written. 
The PICO (Patient-Intervention-Control-Outcome) scheme supports this step 
by focusing on a (clinical) question in terms of the specific patient problem 
and is aiding the searcher (info-specialist, librarian) in finding (clinically) 
relevant evidence in the literature.  
Depending on the time-frame and the complexity of the topics,  
options to decide are: 
 Rapid assessment (1-3 months) for single technologies  
 Multiple comparative technologies (3+ months) 
 Comprehensive assessments for complex interventions (6+months) 
 Planning documents  
 Etc. 
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HTA is a multi-disciplinary research activity. Methodologic guidances on the 
actual development of an HTA on  
 Systematic searching (in different databases) 
 Critical Appraisal and quality assessment 
 Extracting and validating of outcome data (on selected patient relevant 
endpoints) 
 Reporting of results 
are to be found elsewhere in manifold handbooks, appraised and synthesized 
in the EUnetHTA methods-guidances [34]. 
While in rapid assessments on single technologies (drugs/devices) an evidence 
analysis of safety and efficacy/effectiveness might be sufficient, the assess-
ments of other technologies require information on also psychological/social/ 
ethical implications, on organizational/professional effects and economic im-
pact of a technology. Besides background materials on the health problem in 
question and on the technology (intervention) itself, it is essential to start with 
assessing safety and efficacy/effectiveness first – provided information on (low, 
acceptable) risk and (high, certain) benefit given –, since subsequent assess-
ments (e.g. on economics) might not be needed if previous ones already pro-
vided a negative answer.  
For each of the “domains” (safety, efficacy/effectiveness etc) studies are iden-
tified (in several sources/databases), selected according to pre-defined criteria, 
the quality of the evidence is appraised, the evidence extracted and the pa-
tient-relevant information synthesized. The results from all outcomes form 
the basis of the discussion and the conclusion of the HTA [40] 
Peer reviewing as a measure of external quality control is considered an essen-
tial last step before publication. 
Options for the evidence synthesis (HTA) are (also based on the time-frame): 
 Inclusion of unpublished information (grey publications,  
unpublished primary data). 
 Drafting of recommendations (or conclusions only), use of grading 
tools (GRADE). 
 Quality assurance measures: number of peers reviewing the HTA 
(e.g. methodologist and clinical expert or only clinical expert).  
Selection of peers. 
 Conflict of Interest (CoI) statements and their management. 
 Public consultation and stakeholder involvement [45, 46] of final draft. 
Publication of all stakeholder comments and authors´ responses. 
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Figure 3.5-2: Best practice HTA assessment process. Source: [40] 
 
Excursus:  
The EUnetHTA pilot process of rapid assessments of medical devices 
Within EUnetHTA Joint Action 2 a process for piloting rapid assessments of 
relative effectiveness (REA) for other technologies [than pharmaceuticals] 
such as medical devices, surgical interventions or diagnostics was developed. 
In this process, a special focus lies on stakeholder involvement.  
 In the scoping phase of the assessment different stakeholders includ-
ing manufacturers may submit topics for assessment.  
 After a topic has been selected and the cooperating HTA doers have 
been identified, manufacturers hand in their submission file and a 
scoping meeting takes place.  
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 In the meantime a public consultation via the EUnetHTA website col-
lects inputs on the draft project plan from a wider group of stakehold-
ers including consumers, patients and medical experts. The authors 
of the rapid assessment answer all comments.  
 The resulting final project plan is the basis for the ensuing assessment 
phase with two review cycles, one internal among the project group of 
HTA doers and one external with at least two outside experts. The 
comments of the external reviewers are answered and later published 
together with the report.  
After medical editing and formatting, the final version of the pilot relative 
effectiveness assessment is translated for incorporation into national and lo-
cal HTA reports. The relative effectiveness assessment does not contain rec-
ommendations regarding reimbursement. All HTA doers involved in the pro-
cess as well as the external reviewers complete a declaration of interest to 
make potential conflicts of interest transparent. EUnetHTA’s proposed pro-
cess comes with a detailed timeline [47] and is visualized in Figure 3.5-3. 
 
Figure 3.5-3: EUnetHTA Joint Action 2 Pilot process of rapid assessments of “other technologies” such as medical 
devices, surgical interventions or diagnostics. Source: simplified from [47] 
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Dissemination, communication, publication 
A crucial, often underestimated activity is that of dissemination of the HTA-
products. The target audience of HTA is frequently not limited to policy 
makers. The ability to increase the use of the findings not only by decision 
makers, but also by clinicians is part of a changing culture towards evidence-
based policy making and evidence-based clinical practice [48]. The aware-
ness that dissemination activities need to be intensified increased in recent 
years.  
Options are 
 Passive dissemination via website access or open access with 1-time 
information for identified target group (e.g. clinicians). 
 Active dissemination via presentations in national clinical fora. 
 Active awareness raising in for a of decision-makers. 
 Active network-management and communication (starting with  
inclusion of clinicians in scoping and peer-review). 
 Patient-information.  
 
From assessment to appraisal to structured decision-making [49] 
HTA is based on a stringent methodology giving special importance to the 
traceability of the results and to equi-distance to interest groups in order to 
avoid undue influence. In some, but not all instances scientific evidence of 
sufficiently high quality that can directly lead to a clear-cut policy decision is 
lacking. In addition uncertainty and social or institutional values (e.g. equity) 
need to be addressed. As a result the need for an additional value-based ac-
tivity arises. Contextualizing the evidence and framing recommendations is 
carried out in an appraisal of the evidence synthesized in the prior assess-
ment step. 
A few European countries (UK, NL) make a clear distinction between HTA 
(with or without recommendations developed), Appraisal (for recommenda-
tions in a more political environment) and final decision-making. If so, the 
appraisal (documentation) is rarely publicly accessible. Many, though not 
all, committees lay down transparent appraisal criteria in considerable detail 
(Model: OHTAC/Ontario or NSC/UK), sometimes criteria are general in na-
ture (Model: G-BA/Germany), some committees strive towards operationali-
zation (Model: ELGK/Switzerland). How criteria are weighted against each 
other is only rarely addressed explicitly, and if, only cursory. 
Options to consider: 
 Establishment of transparent appraisal process (criteria for composi-
tion of committee-members, terms of reference for decision-making, 
CoI-management, appraisal criteria, procedural rules etc.) 
 Consensual appraisal (discussion) of HTA and recommendation to de-
cision-maker. Ev. documentation of argument in case of deviation from 
assessment. 
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Excursus: Beyond static HTA reports: Ontario’s Evidence Review Process 
In 2003 the Canadian province Ontario started to develop a single portal for 
the uptake and diffusion of health technologies based on an approach that is 
evidentiary, bottom-up, transparent, accountable and open to appeal [50]. 
Health interventions reviewed include a wide range of procedures, services, 
and devices. Applications for conducting a review are accepted from all in-
terested parties, including patients and members of the public. Broad stake-
holder engagement via a professional and public consultation process, in which 
recommendations are open for comment, is encouraged. When there is insuf-
ficient evidence on the safety, the effectiveness and/or the cost-effectiveness of 
a health intervention, a so called “field evaluation” designed to inform policy 
and funding decisions prior to making long-term commitments is commis-
sioned. [51, 52]. Figure 3.5-4 illustrates Ontario’s Evidence Review Process. 
 
Figure 3.5-4: Ontario Evidence Review Process. Source: [53] 
Abbreviations: HQO ... Health Quality Ontario,  
OHTAC ... Ontario Health Technology Advisory Committee 
Ontario’s evidence review process has changed the way policy makers view 
and use health technology analyses. As opposed to the traditional static HTA 
report that does not address the needs of decision makers, the Ontario pro-
cess is seen as more relevant, responsive and dynamic [51]. 
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Evaluation of impact 
To legitimize – publicly financed – HTA research, as well as to guarantee ben-
efits of HTA research and to prioritize future research, there is need to eval-
uate whether the work thus far has had an impact on the national health care 
system. The HTA research should ultimately result in more efficient use of 
resources and it should support the sustainability of a public health care sys-
tem. Not least, HTA intends to contribute to improved population health. It 
is therefore an inherent characteristic of HTA that the research results and 
its ‘products’ are to be used by the defined target groups [54, 55].  
Conceptual frameworks for impact-evaluations propose that impact is defined 
broadly: not only economic impact on decreased expenditures due to HTA re-
commendations and the use of HTA for investment and reimbursement deci-
sions, but also overall increased knowledge about evidence-based medicine 
and an “HTA culture” (e.g. in media reporting of new interventions, in pub-
lic demand for evidence for investments, distinction between consensus-based 
and evidence-based clinical guidelines) might be the influence of HTA [56]. 
 
“Good practice” HTA products for  
the assessment of medical devices: 4 examples 
mini-HTA, Denmark [15] 
In cooperation with local HTA environments a flexible decision support tool 
was developed for the use of hospital management when contemplating the 
introduction of a new health technology. A mini-HTA can easily be incorpo-
rated into budget and planning processes. A mini-HTA consists of a form and 
an accompanying guide. The form, or quick check list, contains 26 questions 
concerning the prerequisites for and consequences of using the new health 
technology. The questions are grouped into the five domains “Introduction” 
(e.g. “Who is the proposor (hospital, department, person)?”), “Technology” 
(e.g. “On which indication will the proposal be used?”), “Patient” (e.g. “Does 
the proposal imply any risks, adverse effects or other adverse events?”), “Or-
ganisation” (e.g. “Has the proposal been implemented in other hospitals na-
tionally or internationally?”) and finally “Economy” (e.g. “Are there any start-
up costs of the equipment, rebuilding, training etc.?”). The answers to the 
questions provide a brief basis for decisions (2-5 pages) and take 1-2 days to 
complete (excluding time spent on information retrieval and assessment, as 
well as time for economic calculations). A mini-HTA offers decision support 
for a specific environment very quickly. 
Systematic reviews supporting the annual update  
of a national inpatient case-mix funding system, Austria [13] 
Each year, the federal ministry of health receives suggestions for new medi-
cal interventions to be reimbursed within the national inpatient case-mix fund-
ing system. These interventions are prioritized by the ministry and contract-
ed out for assessment to an independent HTA agency. The efficacy and safe-
ty of these interventions are assessed in systematic reviews. Each contains a 
summary of the scientific evidence according to the GRADE scheme and a re-
commendation. The production and external review takes four months. These 
documents are available online in English. 
legitimization for HTA 
guarantee of benefits 
for more efficient use of 
resources 
broad definition  
of impact  
increase of efficient 
resource-use, but also 
increased public 
understanding 
Danish mini-HTA 
format geared towards 
decision situation in a 
hospital under time 
constraint 
 
easily incorporated  
into hospital planning 
processes 
annual assessments of 
interventions for update 
of Austrian hospital 
benefit catalogue 
Background analyses for HTA Strategy 
LBI-HTA | 2015 73 
Traffic light symbols of the MUMM program, Finland [16] 
The collaborative MUMM program between the Finnish national HTA agen-
cy and Finnish hospital districts was started in 2006 to offer critically ap-
praised decision support on effectiveness, safety and costs based on a system-
atic search of the literature. A secondary aim of MUMM is to foster evidence 
based practice in Finnish hospital. A MUMM review group consists of up to 
three clinical experts and up to three HTA agency staff. MUMM uses the 
traffic light model (compare Figure 3.5-5 below) to express the results of a 
review in the form of a direct recommendation: use (green), conditional use 
(orange), do not use (red). 
 
Figure 3.5-5: Traffic light symbols for direct recommendation, source: MUMM, Finland 
This form of presentation gained wide attention in the Finnish health care 
system. People who do not directly know of the MUMM program or of HTA 
can be found talking about “green lights” or “yellow lights” or “red lights”. 
Only the abstracts of the Finnish MUMM reviews published since 2007 are 
available in English online. [57] 
Comparison of competing technologies via Matrix4Value, Spain [58] 
Matrix4Value is a decision-support tool developed by Hospital Clinic of Bar-
celona for prioritizing new competing health technologies after their assess-
ment using the mini-HTA approach. An overall score for each health tech-
nology is calculated and then plotted in a value/risk matrix. By visually show-
ing how health technologies are placed relatively to each other in a risk-value 
matrix, this tool assists the decision-making process. It provides more clear-
cut information for the prioritization of health technology investments un-
der a fixed budget scenario prevalent in hospital settings. Table 3.5-1 below 
illustrates exemplary values for a certain medical device in comparison to a 
competing technology.  
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Table 3.5-1: Exemplary values for a certain medical device, source: Matrix4Value [58] 
Value 
Safety Better 
Efficacy/Effectiveness Equal 
Impact on patient Better 
Cost-effectiveness is available Yes 
Quality of evidence Moderate-low 
Innovativeness degree Moderate 
Risk 
Impact on staff Less staff required 
Impact on physical space Not applicable 
Impact on health care Moderate 
Incremental cost Lower 
Net cost Not applicable 
Investment effort High 
 
 
3.5.2 Analysis of HTA processes (and products) 
in Lithuania  
As stated earlier in more detail (see description in 3.1.2.2), the responsibility 
for producing HTAs lies with authorities under the MoH: SHAA for medical 
devices and IoH for public health. For pharmaceuticals SMCA is at this stage 
not active in producing HTAs. SHAA has laid out internal procedures for 
HTA. In a current EU project capacity for HTA is being built at SHAA. The 
development of IoH’s internal procedures for HTA is presently being final-
ized in a second EU project for capacity building for HTA, this time at IoH. 
Topic identification and prioritization 
SHAA conducts its HTAs on medical devices (so far 2 completed and 4 on-
going) mostly following an application by a manufacturer but also on topics 
suggested by the MoH and by the National Cancer Institute. IoH identified 
the topics for its first HTA reports on public health topics (so far 3 complet-
ed and 2 ongoing) through an internal pilot process that included prioritiza-
tion of topics. Also the MoH suggested topics for public health HTAs. 
Deliberation on HTAs and decision on implementation 
SHAA’s HTA Commission has in practice not been meeting for some time. 
HTAs produced by SHAA are in fact submitted directly to the MoH HTA 
Committee, which can make recommendations to the Minister. The Minis-
ter can decide on steps towards the implementation of results from an HTA. 
Also the applying manufacturer receives the SHAA HTA on its medical de-
vice. HTAs produced by IoH are currently also submitted directly to the MoH 
HTA Committee. 
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Evidence component in pharma-reimbursement 
While Lithuania at present undertakes no HTA activity in the narrower sense 
for pharmaceuticals, an established process with a clear structure for the ap-
plication of a pharmaceutical for NHIF reimbursement (positive list) has been 
in place for over a decade. This process instituted a mandatory pharmaco-
ecomomic evidence component. The applicant submits the dossier to the MoH 
(Pharmaceutical Reimbursement Commission and Compulsory Health In-
surance Council). The dossier includes a pharmaco-economic report, com-
missioned externally by the applying pharmaceutical company itself. The two 
bodies deliver separate reimbursement recommendations to the Minister, who 
takes the final decision. The HTA processes for medical devices and public 
health and the evidence component in reimbursement decisions for pharma-
ceuticals described above are illustrated in Figure 3.5-6 below. 
 
Figure 3.5-6: HTA processes in Lithuania 
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Deficiencies 
Currently Lithuania lacks a transparent and coordinated process for HTA. 
The independence (see description of independence in 3.3.1) of HTA doers 
from policy makers and from potentially conflicting regulatory functions lo-
cated at their organization (e.g. SHAA) is currently not safeguarded. The role 
of HTA in informed decision-making is not defined. There are no effective 
criteria in place for when to conduct an HTA (e.g. ahead of planned invest-
ment in a medical device costing above a certain threshold). For medical de-
vices there is no detailed planning document for expensive medical devices 
(number and location of PET, MRI, CT etc.) based on evidence from HTAs 
that would yield an explicit guideline for investments. While one potential 
key beneficiary of evidence based decision support through HTA in Lithua-
nia, the MoH, has an active say in the choice of topics for HTAs for medical 
devices and for public health, the other, NHIF, is not directly involved at all.  
For medical devices there is no proactive public interest agenda setting for 
HTA topics (e.g. horizon scanning and disinvestment) and for pharmaceuti-
cals there is none for the current reimbursement system (e.g. identification 
of candidates for removal from positive list); instead manufacturers play the 
key role in determining the HTA topics. Currently broader health care sys-
tem level topics (e.g. concentration of neurosurgery or of specialized cancer 
services in centers of excellence) are not addressed through HTAs. There is 
no coordination in place between the doers of HTA (currently SHAA and 
IoH, in the future supposedly also SMCA). SHAA and IoH do not cooperate 
on topics that transcend their responsibilities for medical devices and public 
health respectively. Safeguards for the quality of HTA reports are not estab-
lished. There is no clear pathway from completion of an HTA report towards 
a decision on implementation (or not) and then on to implementation. While 
the process of application for reimbursement of pharmaceuticals by NHIF is 
explicit and clear, the quality of the evidence-based component and the trans-
parency of the ensuing decision making are not. Pharmaceutical companies 
currently pay experts they themselves select to compile the required pharma-
co-economic report. 
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4 Summary and Discussion 
Legal framework and regulatory context of decision-making 
The regulatory environment for decision-making in health care is essential for 
the actual role of HTA. In most countries, binding legal requirements to con-
sider scientific evidence of effectiveness, safety or cost-effectiveness before a 
decision on Public Health investments, on new equipment or benefit-catalogues 
is made are rare. Nevertheless, HTA has the greatest impact if it is carried out 
for a concrete policy decision. Most HTA agencies in Europe are advisory bod-
ies and have no regulatory function in order to safeguard the independence of 
HTA from vested interests. 
Lithuania’s health system with a single social health insurance fund is highly 
centralized. The MoH has the key role and many decisions are ultimately tak-
en by the minister of health. The MoH also administers EU structural funds, 
which account for 60% of capital investment in the health sector. Forward 
looking health policy documents passed by Parliament stabilize governance.  
The introduction of HTA into decision-making processes has been initiated sev-
eral times (1993, 1999), though has not been successful. Prioritization of health 
resource allocation is still mostly based on a politically driven, rather than ev-
idence-based, decision-making process.  
HTA activities are in their early stages and fragmented.  
Utilization (need and demand) of HTA in health care and barriers 
Technology assessments are useful to a wide range of decision-makers in health 
care, including government policy makers and social health insurance admin-
istrators, for the following: 
 Decision to include or exclude an intervention (drug, procedure, device) 
in benefit catalogue or positive/negative list. 
 Decisions on disinvestment from interventions that are obsolete or  
unsafe or of uncertain benefit. 
 Decisions on planning and localization of an expensive device  
(e.g. PET) or a specialized service (e.g. neurosurgery). 
 Decisions on quality improvement through HTA input for clinical path-
ways, evidence-based guidelines and development of quality indicators 
for patient relevant outcomes. 
In order to support decision-makers, the relevant HTA needs to be of good 
quality (valid, reliable, with a clear message) and available on time for the de-
cision. HTA should fulfill a bridge function between science, policy making 
and practice. For this HTA doers have to understand the needs and priorities 
of policy makers. In the same way policy makers have to be familiar with and 
open to the potential of evidence to inform decisions. Human and financial re-
sources need to be available to produce the relevant HTA reports in good qual-
ity. Barriers to the utilization of HTAs include a resistance to a transition from 
“eminence based” to “evidence based” decision-making coming from profes-
sional (clinical) bodies, from management or from policy makers. 
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Lithuania is understood to need a rational system of decision making on in-
vestment and reimbursement that includes an HTA function. There are pri-
marily two institutions that require decision support for the allocation of their 
limited financial resources for reimbursement and investment: MoH and NHIF. 
When reimbursing a medical device or pharmaceutical, the NHIF also needs 
to determine at what stage of the life-cycle of a technology (early on or later) 
to include it in the benefit catalogue. To make it onto the positive list of NHIF 
reimbursed pharmaceuticals, an evidence based pharmaco-economic dossier is 
required as part of the application process. When the MoH is implementing 
strategies or programs, like the current EU funding program with its special 
focus on public health and investment in evidence based practice, the MoH re-
quires decision support for determining which measures are best suited for the 
task.  
Barriers for HTA in Lithuania are the lack of a clear and transparent HTA 
process (coordination of HTA demand and production, proactive prioritizing 
of HTA topics, quality criteria for HTAs, clear pathway towards implementa-
tion) and the compromised independence of HTA doers from policy makers, 
regulators and industry. The value of HTA needs to be appreciated by the po-
litical echelon. 
HTA institutionalization and financing 
There is no one “best practice model” of HTA institutionalization in Europe. 
HTA can be located at a single centralized HTA agency or there can be decen-
tralized and regionalized HTA institutions. Some countries organize their HTA 
activities in coordinated networks of HTA doers. Most institutions are publicly 
funded and closely associated with government, ministries of health or social 
health insurance. Some institutions are academic.  
The credibility of HTA depends on independence from interest groups while 
at the same time maintaining close contact with decision makers (see descrip-
tion of independence in 3.3.1). For this, stable long term funding of HTA ac-
tivities and mechanisms against political interference are essential. 
In the process of developing a national HTA infrastructure, there is a need to 
“organize” these critical requirements and to secure independence by setting 
up adequate governance structures. The independence from policy makers and 
special interests is regulated in most countries. Mechanisms to safeguard in-
dependence include clear and transparent process descriptions, the monitor-
ing of the scientific quality of HTAs, external peer-review for all HTA prod-
ucts and the separation of recommendations based on an HTA and the policy 
decision. 
HTA activities in Lithuania are fragmented. An independent HTA institution 
has never been established. Two institutions under the MoH currently perform 
HTAs exclusively on medical devices (SHAA is currently working on 4 topics, 
having completed 6) and HTAs on public health issues respectively (IoH is cur-
rently working on 2 topics, having completed 3). Temporary funding for HTA 
capacity building at SHAA and IoH comes from two EU projects (2013-2015). 
HTA features both in the current National Health Program adopted by Par-
liament and in the present government’s action plan. The MoH established an 
HTA Committee in 2014 to coordinate HTA activities, to develop a system for 
the prioritization of health technologies to assess, to examine completed HTA 
reports and to give recommendations to the minister of health on implementa-
tion.  
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Human resources for HTA and capacity building 
Decision-making about the adoption of new technologies is part of the opera-
tional routine of health authorities, funders and service providers. These deci-
sions are frequently based on unilateral information from a single expert or 
from industry. The challenge is to change the decision-making culture towards 
evidence-based decisions. This change requires – beside the firm commitment 
from health policy (health authorities) – sufficient national capacities to carry 
out HTA and implement it: HTA core staff (systematic literature search, criti-
cal appraisal of studies, evidence synthesis), training to understand and imple-
ment HTA for policy makers, clinicians and health care managers plus aca-
demic research capacity in HTA methodologies. HTA is by definition multi-
disciplinary and needs to bring together experts from many fields. 
For small countries strong external HTA-networks (EUnetHTA) and partner-
institutions are important, to increase the national efficiency by collaborating 
in joint assessments and by building upon other HTA-agency´s outputs. 
In Lithuania there is only limited capacity building for HTA outside of the two 
ongoing projects funded by the EU (2013-2015) for SHAA and IoH. But the role 
of e.g. the LUHS in providing training on HTA (critical appraisal for system-
atic reviews, economic evaluation, etc.) is essential. In the future a considera-
ble challenge for Lithuania will be to retain trained HTA experts in the public 
sector (and even in the country).  
HTA processes and products, special focus assessment of medical devices 
To bridge the domains of medical research and health policy-making, HTA of-
fers a clear structure for transparent processes and products. This transparen-
cy is of utmost importance to make the results valid, reliable and open to scru-
tiny. All along this process, HTA transparently discloses its methods, includ-
ing those for the management of conflict of interest to avoid undue influence 
from special interests and those for public consultation and stakeholder in-
volvement.  
An HTA is initiated either through the identification of an assessment need in 
the health system (e.g. by the MoH or by social insurance) or through the sub-
mission of an assessment request by an applicant (e.g. manufacturer of a med-
ical device), most HTA regimes combine the two. Priorities for the commis-
sioning of HTAs have to be set, and often aim to identify high volume and high 
cost interventions with a high amount of uncertainty. Next the prioritized pol-
icy question that reflects the context in which the assessment is carried out is 
translated to a research question that can give an evidence-based answer to the 
policy problem. An evidence analysis of safety and effectiveness may be suf-
ficient for rapid assessments of single technologies (drugs, medical devices). 
Comparing multiple technologies or comprehensive assessments of complex in-
terventions in addition require information on psychological/social/ethical im-
plications, on organizational effects and on economic impact. For each of these 
domains the quality of the available evidence is appraised, the evidence is ex-
tracted and patient relevant outcomes are synthesized. Before the publication 
of an HTA report, peer review as an external quality control is considered es-
sential. A key, often underestimated activity is the dissemination of HTA prod-
ucts. During the appraisal of the evidence synthesized, it is contextualized and 
recommendations are derived. The European HTA cooperation EUnetHTA 
produced templates for processes and products of good HTA practice.  
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In Lithuania HTA is only in its infancy. SHAA, an institution under the MoH, 
conducts HTA on medical devices, mostly following an application by a man-
ufacturer. IoH, another institution under the MoH, is responsible for HTAs on 
public health topics. There is presently no HTA activity beyond medical devices 
and public health. The resulting HTA reports are mostly suggested by the MoH. 
These HTA reports are submitted to the MoH HTA Committee that can make 
recommendations to the minister, who ultimately decides on implementation 
measures. A coordinated HTA process for Lithuania is not in place yet, nei-
ther are there explicit criteria for topic selection for HTAs, nor for the quality 
of HTA reports. The independence of HTA doers from policy makers and from 
potentially conflicting regulatory functions at their organization (e.g. in the case 
of HTA on medical devices at SHAA that is responsible for regulating medical 
devices) is currently not safeguarded. There is as yet no clear path from HTA 
towards implementation of recommendations. NHIF, the main funder of health-
care services in Lithuania and as such potentially a major user of HTA results, 
is presently only peripherally involved in HTA processes through membership 
in the MoH HTA Committee. 
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5 Conclusion and Recommendations 
The recommendations developed (and activities proposed) based on this report 
are published in a separate document:   
“HTA-Strategy for Lithuania” (http://eprints.hta.lbg.ac.at/1064).  
They should be considered as a contribution to the Lithuanian HTA-Strategy. 
The ultimate success of the HTA-Strategy is strongly dependent on if and how 
Lithuanian health sector stakeholders take the ownership of the Strategy and 
establish a process for evidence-based decision support. 
 
recommendations 
published in separate 
document 
should be considered 
contribution (only) 
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